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Abstract  
 CD4+ T cells are essential for proper function of the immune system.  Many 
facets of an immune response are dependent on help from CD4+ T cells to become 
activated and exhibit effector function.  Memory CD4+ T cells are a differentiated subset 
of T helper cells that give rise to long-lasted protective immunity.   Differentiation to a 
memory phenotype from a naïve T cell that has never encountered antigen requires two 
signals.  Costimulatory molecules send a second signal into naïve T cells that follows 
stimulation of the T cell receptor and greatly affects how naïve T cells activate and 
differentiate.   The present work centers on the ability of the costimulatory molecule 
Intercellular Adhesion Molecile-1 (ICAM-1) to induce activation and differentiation of 
CD4+ naïve T cells to effector and memory phenotypes. 
 We observed that costimulation through ICAM-1 generates a central memory-like 
population that is capable of migration to the lymph nodes and to a lesser extent the 
intestine.  ICAM-1 costimulation is also capable of inducing memory differentiation after 
a short duration of signal but long-term costimulation is needed to generate a sizable 
population.   In addition, costimulation of CD4+ naïve T cells from older individuals 
through ICAM-1 is able to produce memory cells more so than other costimulatory 
molecules.  This suggesting that ICAM-1 could be utilized to help restore immune 
function during senescence. 
 ICAM-1 and its ligand leukocyte function-associated antigen-1 (LFA-1) also 
provide targets for blocking self-reactive T cells in autoimmune diseases.  Peptides 
against ICAM-1 and LFA-1 were used in the type I diabetes NOD mouse model.  We 
observed a significant delay in symptoms with therapeutically treated mice compared to 
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saline control mice and stopped T cell infiltration of the pancreatic islets.  Additionally, T 
cells from treated mice were no longer able to respond to β-cell antigen indicating a shut 
down of the autoreactive immune response.  
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Introduction and general background information 
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The Adaptive Immune Response 
 
 The immune system has two main branches: the adaptive immune response and 
the innate immune response.  The innate response is not antigen specific but provides an 
immediate response to pathogens.  The adaptive side takes longer to respond to specific 
antigen and yields immunological memory for a more efficient secondary response.  The 
adaptive immune system can be broken down further into the humoral and cell-mediated 
immune response.   Antibody production by plasma cells (derived from B cells) is the 
effector outcome of the humoral response.  Antibodies can bind to bacteria and viruses to 
neutralize them, tag elements for opsonization, aggluntinate to form insoluble complexes 
for clearance and initiate components of complement pathways.  The cell-mediated 
immune response is driven by CD8+ cytotoxic T lymphocytes (TC cells) that target and 
kill infected cells using perforin and granzyme pathways.  Macrophages are activated in 
the cell-mediated pathway and function to phagocytize pathogens and foreign elements.  
CD4+ helper T cells (TH cells) play a role in both sides of the adaptive immune system.  
Th1 cells secrete interleukin-2 (IL-2), interferon-gamma (IFN-γ) and interleukin-12 (IL-
12) that help to activate the cell-mediated branch of the adaptive immune system and 
inhibit the humoral response.  Th2 cells do the opposite and promote the activation of 
humoral immunity and B cell activity while inhibiting Th1 function by secreting 
interleukins-4, -5, -10 and -13 (IL-4, IL-5, IL-10 and IL-13) (Fig. 1.1).   Both sides of the 
immune system can be controlled by regulatory T cells (Treg) that secrete IL-10 and 
TGF-β to suppress other immune cells or use granzyme B and perforin to suppress via 
cell-to-cell contact (1, 2).  Regulatory T cells are important for downregulation of the  
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Figure 1.1 
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Figure 1.1.  Model of the adaptive immune response.  CD4+ T cells regulate both the 
cell-mediated (CD8+ T cell and macrophages) and hurmoral (B cell) branches of the 
immune response by secretion of soluble mediators. Regulatory T cells suppress the 
immune response.    
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immune system after an immune response and suppression of possible self-reactive 
immune cells.   
 
 
T cell signaling, activation and differentiation 
 
 Naïve T cells are a subset of the T cell compartment that have recently emerged 
from the thymus following development to a functional cell but have not yet encountered 
antigen.  They circulate through the periphery and secondary lymphoid organs looking 
for their specific antigen, which is presented by an antigen presenting cell (APC).  Upon 
antigen recognition and binding, naïve T cells become activated to clonally expand and 
differentiate into an effector phenotype (Fig. 1.2).  Effector cells are capable of secreting 
cytokines and other soluble molecules that (i) signal to activate or (ii) suppress other 
immune cells, (iii) direct cells where to go in the body and (iv) participate in elimination 
of foreign elements.  Effector cells have a short life span and following antigen clearance 
the majority of effector cells undergo activation-induced cell death (AICD).  A small 
number of cells survive after the immune response has been resolved and become 
memory T cells (Fig. 1.2).  Memory T cells are long-lived in the body and able to 
activate quickly upon secondary challenge with the same antigen. 
 
Signal 1: TCR/CD3 
 Naïve T cells require two signals to become fully activated.  The first signal is 
antigen specific and received through the T cell receptor (TCR) when it binds to its  
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Figure 1.2 
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Figure 1.2.  Model of naïve T cell activation.  Upon receiving an antigen signal, naïve T 
cells can activate, proliferate and differentiate into effector cells.  The effector population 
will die by apoptosis after the immune response has taken place.  Memory T cells arise 
from either an effector population or directly following priming of the naïve cell (to be 
discussed in chapter 2).
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cognate peptide antigen in the context of the major histocompatibility complex (MHC).  
The MHC is referred to as human leukocyte antigen (HLA) in humans and is expressed 
in two forms that designate the class and stimulating potential of the molecule.  MHC 
class I presents antigenic peptides of 8-10 amino acids to CD8+ T cells.  Class I is 
formed by one alpha subunit containing three domains and a β2-microglobulin molecule.  
MHC class II is comprised of two protein subunits (alpha and beta) and presents a larger 
peptide, about 13-25 amino acids, to CD4+ T cells.  The T cell receptor for CD4+ and 
CD8+ T cells is a heterodimer that contains alpha and beta subunits and is associated 
with the CD3 complex.  The CD3 complex is formed by delta, gamma and two epsilon 
polypeptides and two zeta chains (assembled as γ/ε, δ/ε and ζ/ζ dimers) and is essential 
for signal transduction.  The CD3 chains contain immunoreceptor tyrosine-based 
activation motifs (ITAMs) that, upon TCR:antigen binding, become phosphorylated on 
tyrosine residues.  This allows for activation of Src family kinases (Lck and Fyn) and 
Zap70, phosphorylation of transmembrane adaptor proteins and leads to activation of 
various transcription factor pathways (3, 4).   
 If the T cell only receives one signal through the TCR/CD3 complex, the cell will 
fail to activate and become anergic or die by apoptosis.  T cells must receive a second 
signal through a costimulatory molecule.  The costimulatory signal may be received 
through CD28, lymphocyte function-associated antigen-1 (LFA-1), intercellular adhesion 
molecule-1 (ICAM-1) as well as any of several other T cell surface proteins (Fig. 1.3).   
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Figure 1.3 
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Figure 1.3.  Model of T cell signal.  Naïve T cells must receive two signals to become 
activated.  The first signal is received through the TCR/CD3 complex by specific antigen 
bound to the MHC.  The second signal may be received through, for example, CD28, 
LFA-1 or ICAM-1 on the T cell.
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Signal 2: CD28 
 CD28 belongs to the immunoglobulin family of costimulatory molecules and is 
expressed as a glycosylated, disulfide-linked homodimer and is expressed on most T 
cells.  The best-studied ligands for CD28 are B7.1 (CD80) and B7.2 (CD86) both of 
which send a signal through CD28 leading to phosphorylation of tyrosine residues and 
proline rich regions on the cytoplasmic tail that provide docking sites for src homology-2 
(SH2) and src homology-3 (SH3) domain containing proteins (5).  The binding of adaptor 
proteins to the cytoplasmic tail of CD28 allows for downstream activation of JNK, 
PLCγ1, PI 3-kinase (PI3K), NFAT and NFκB (5).  Activation of the PI3K pathway 
induces the production of phosphatidylinositol (3,4)- bisphosphate (PIP2) and 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which recruit phosphoinositide-
dependent kinase 1 (PDK1) and PKB/Akt and lead to an increase in NFκB and NFAT 
transcription of Bcl-XL, IL-2 and other factors to promote cell survival and proliferation 
(6, 7).  Costimulation through CD28 also promotes the development of both Th1 and Th2 
subsets and differentiation to a memory phenotype (8) (Table 1.1).   
 
Signal 2: Leukocyte function-associated antigen-1 (LFA-1) 
 LFA-1 is a member of the β2 integrin family and is present on all leukocytes.  
The ligands for LFA-1 are adhesion molecules ICAM-1, ICAM-2 and ICAM-3.   LFA-1 
forms a heterodimeric complex of the α subunit (CD11a) and β subunit (CD18).  On a 
resting cell surface, LFA-1 has an occluded conformation that changes to an open, active 
form in response to inside-out signaling and leads to the phosphorylation of the LFA-1 
cytoplasmic domain.  Signaling through LFA-1 has been linked to the tyrosine kinase  
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Table 1.1 
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phosphatidylinositol pathway that activates phospholipase C-γ1 (PLC-γ1) and induction 
of Ca2+ mobilization and to induce NFκB and NFAT transcription factors (9).  The LFA-
1 signal pathway leads to an initial burst of cell proliferation but limited IL-2 production 
or protection from apoptosis (10, 11).  Cells costimulated through LFA-1 differentiate to 
a Th1 effector phenotype (12) but this does not lead to the development of 
immunological memory (Table 1.1). 
 
 Signal 2: Intercellular adhesion molecule-1 (ICAM-1)  
 Relatively little is known about the signaling events that follow costimulation 
through ICAM-1.  ICAM-1, also designated by CD54, is expressed on many cell types 
including endothelial cells, epithelial cells, monocytes and at low levels on naïve and 
resting T cells but becomes upregulated following activation (13).  ICAM-1 binds to 
ligands LFA-1, Mac-1, p150/95 and CD43. Initially known for its role as a ligand to 
LFA-1 on leukocytes during immune cell extravasation into inflamed tissue, ICAM-1 has 
more recently been shown to be a costimulatory molecule on T cells (14, 15). ICAM-1 is 
a member of the immunoglobulin (Ig) superfamily.  It has five glycosylated extracellular 
Ig domains that are formed by disulfide bridges, a transmembrane domain and a short 
cytoplasmic tail (Fig. 1.4) (16).  The entire ICAM-1 molecule is 505 amino acids with 
only 28 of those amino acids making up the C-terminal cytoplasmic domain.  The 
cytoplasmic tail contains a tyrosine residue that can be phosphorylated, an SH3 domain 
and many positively charged amino acids that could all possibly be utilized in binding or 
recruitment of signal proteins (17).  Signaling of ICAM-1 on endothelial cells suggests 
that the cytoplasmic tail can interact with α-actinin, ezrin, moesin, β –tubulin and recruits  
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Figure 1.4 
 NRQRKIKKYRLQQAQKGTPMKPNTQATPP 
	   15	  
Figure 1.4.  Structure of the ICAM-1 molecule and amino acid sequence of the 
cytoplasmic tail.  ICAM-1 contains 5 Ig extracellular domains at the N-terminus that are 
formed from disulfide bridges (S-S), a transmembrane region and a short cytoplasmic tail 
at the C-terminus.  Circles on the extracellular portion indicate possible glycosylation 
sites.  The amino acid sequence of the cytoplasmic tail is indicated below the ICAM-1 
structure.  The box indicates the SH3 domain.
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Src-homology domain 2 containing phosphatase 2 (SHP-2) (18, 19).  There is also 
evidence that ICAM-1 signalling initiates downstream activation of PKC, Src kinases, 
MAP kinases, Rho, and focal adhesion kinase (FAK) (18-20).  Many members of our lab 
have worked on identifying the signaling proteins that associate with the ICAM-1 
cytoplasmic tail on T cells when ICAM-1 is cross-linked in solution.  Cdc2 and MAPK 
are constitutively associated with ICAM-1 and immediately after stimulation a complex 
that includes Zap-70, Fyn, P-Lck, TCRβ and CD3ζ chains becomes transiently associated 
(21, unpublished data) (Fig. 1.5).   
 After a naïve T cell receives a costimulatory signal through ICAM-1 it undergoes 
activation that leads to proliferation and significant production of IL-2 slightly later than 
IL-2 secretion with CD28 costimulation (15).  Costimulation through ICAM-1 also 
induces protection from apoptosis and cell differentiation to effector and memory 
phenotypes (15).  Memory-like cells that were generated by costimulation through 
ICAM-1 were able to proliferate and secrete effector cytokines much quicker and with 
less signal that naïve T cells (15). 
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Figure 1.5 
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Figure 1.5.  ICAM-1 signaling complex.  Cdc2 and MAPK are constitutively associated 
with the cytoplasmic tail of ICAM-1.  Once a signal is sent into the T cell through ICAM-
1, Zap-70, Fyn, P-Lck, TCRβ, CD3ζ and a not yet identified adaptor protein associate 
with the complex and disassociate within ten minutes.  Cdc2 kinase becomes inactivated 
by phosphorylation and then reactivates by 10 minutes (21).
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This dissertation 
 Chapters 3-6 will examine the role of ICAM-1 in the activation and differentiation 
of CD4+ naïve T cells to effector and memory cells. Specifically, we will evaluate the 
duration of signal needed to drive differentiation and homing ability of the differentiated 
cells and how different costimulatory signals impact differentiation.   The affect that 
immunosenescence has on the ability of naïve T cells to respond to costimulatory signals 
will also determined.  Finally, we will describe a method to differentiate murine CD4+ 
and naïve T cells to a central memory phenotype.  Background information for each 
chapter will be given in more detail in their individual introductions. 
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 T cells in Type I Diabetes 
 
 Autoimmune disease is the result of the loss of central or peripheral tolerance that 
allows the immune system to attack self-antigens.  Auto-reactive T cells are eliminated 
before they mature and leave the thymus by mechanisms of central tolerance. T cells that 
escape the thymus and react to self antigens are controlled by peripheral tolerance using 
regulatory components of the immune system.  When this balance malfunctions, auto-
reactive cells can begin to attack and destroy self-tissue as is the case with type I diabetes 
(T1D).  T1D is a T cell driven disease where self-reactive T cells attack β-cells in the 
islets of Langerhans within the pancreas.  β-cells produce insulin that is necessary to 
maintain normal levels of glucose in the blood.  Insulin, glucose and glucagon form a 
tightly regulated negative feedback loop that controls plasma glucose homeostasis.  
Glucagon is a hormone produced by islet α-cells that promotes gluconeogenesis, the 
production of glucose from carbon substrates, and glycogenolysis, the breakdown of 
glycogen (the stored form of glucose) to glucose (22).  When the blood glucose level 
becomes elevated, it induces the secretion of insulin from the β-cells to promote glucose 
uptake by cells and the use of glucose for energy (22).  The loss of blood glucose 
regulation can lead to ketoacidosis, hypoglycaemia, heart disease, blindness, kidney 
failure and other complications (23-26).   
 T cells involved in T1D respond to a number of islet self-antigens, including 
insulin, glutamic acid decarboxylase 65 (GAD65), insulinoma-associated protein 2 (IA2), 
zinc transporter 8 (ZnT8), and islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP) (27).  Initial recognition of islet autoantigens by T cells occurs in 
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the pancreatic lymph nodes.  Destruction of β-cells during insulitis leads to the release of 
more autoantigens that can be presented by APCs and prime new T cells and result in 
additional islet destruction (28).  Approaches to find therapies for T1D involve inducing 
specific tolerance to known autoantigens (29, 30), blocking of the immune response (31, 
32) and suppressing autoreactivity with regulatory T cells (33).  Some therapeutic 
approaches for T1D have met with limited success and the efficacy of others has yet to be 
determined.   
 
 
This dissertation 
 
 Chapter two examines the use of peptides derived from the contact domains of 
ICAM-1 and LFA-1.  These peptides block the interaction of ICAM-1:LFA-1 and are 
being developed by our lab as a therapy for type I diabetes.  We have evaluated the effect 
that blocking the T cell second signal has on progression of the disease, maintenance of 
islet integrity and the ability of immune cells to respond to specific β-cell antigen or 
mitogenic stimulus.  Specific background about the peptides and the role of T cells in 
T1D will be described in the next chapter.   
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Chapter	  2	  
ICAM-­1:LFA-­1	  blocking	  peptides	  eliminate	  the	  T	  cell	  response	  in	  the	  NOD	  
mouse	  model	  for	  type	  I	  diabetes.	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Introduction 
The autoimmune disease, type I diabetes (T1D) is driven by T cells that are reactive 
against the pancreatic islets of Langerhans. These self-reactive T cells infiltrate islets and 
induce destruction of beta cells, gradually rendering the pancreas unable to control blood 
glucose levels [1].  Each self-reactive T cell is specific for an epitope of one beta cell 
antigen, of which there are several.  In humans, the approximate number of T cell 
specificities at a given time is 100 million of which only a small percentage participates 
in T1D.  A long sought approach to therapy has been to restore self-tolerance by inducing 
death or anergy only in the T cells that are attacking the pancreas while leaving the 
remainder of the uninvolved T cells free to function in defense of the organism.  
The present work uses short peptides to block interaction of the counter receptor 
pair, lymphocyte function associated antigen-1 (LFA-1) and intercellular adhesion 
molecule-1 (ICAM-1), in NOD mice, as a therapeutic approach for T1D.  The proposed 
mechanism is based on the long-standing concept of second signal blockade.  
Engagement of the T cell antigen receptor (TCR) by appropriately presented antigen 
(signal 1) represents the first decision point for the T cell [reviewed in 2, 3].  If the TCR 
has no specificity for the Ag, the complex dissociates and no signal is transmitted, but if 
the Ag is cognate, the T cell will initiate activation. This decision point provides the 
specificity of the T cell response and with T1D, only the disease relevant T cells will 
respond.  To fully activate, the T cell requires a second signal, the most studied of which 
is received by resident CD28, although several additional T cell surface proteins have 
been classified as receivers for a second signal [rev, 3].  This includes both the proteins 
targeted in the present study, ICAM-1 [4] and LFA-1 [5].  With co-delivery of both 
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signals, the T cell activates, proliferates and begins to function.  If signal 1 is delivered 
but signal 2 is prevented, the T cell dies or is rendered anergic.  Thus, the proposed 
induction of tolerance is based on allowing signal 1 (antigen) and preventing signal 2, the 
result of which is to inactivate only the cells presently responding to Ag and have no 
effect on cells not being stimulated by their cognate Ag.  The best of the early examples 
of blockade of LFA-1/ICAM-1 interactions in this manner was facilitation of heart 
transplants in mice [6] using antibodies against both proteins. 
Both LFA-1 and ICAM-1, are resident on the T cell surface, and are known to have 
costimulatory function that can receive a second signal into an activating T cell [3, 4, 7].  
Both LFA-1 and ICAM-1 participate in intercellular adhesion events associated with T 
cell activation and cytotoxic T cell function [8, 9], and both are important for adhesion, 
extravasation and migration of leukocytes.  Migration is facilitated because LFA-1 is 
expressed on all leukocytes and ICAM-1 is expressed on many cell types including 
leukocytes, endothelial and epithelial cells.  Thus, a potential second mechanism of 
action by interfering with interaction of these two is that migration of T cells and other 
leukocytes toward the site of attack may be transiently impaired as well. Because of their 
roles in cell contact, cell migration and T cell activation, LFA-1 and ICAM-1 play an 
important role in the development and maintenance of autoimmune disease [10, 11]. Over 
nearly two decades, antibody blockade of LFA-1 and ICAM-1 interactions has shown 
promise for treating T1D by tolerance induction [12-14] but the promise has not been 
fully realized. 
Current approaches to induce tolerance in TID are directed toward inhibition of 
self-reactive lymphocytes or activation of regulatory components of the immune system, 
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including regulatory T cells; each of these approaches, however, has drawbacks [15, 16]. 
As examples, blockade of T cell costimulatory molecules such as CD28/B7, 
CD40/CD40L or ICAM-1/LFA-1 using antibodies has been explored as a possible 
therapy to treat T1D or assist in islet graft acceptance in NOD mice. These met with 
limited success because the therapy had to be initiated prior to insulitis or required 
blockade of multiple costimulatory pathways [17-20].  Also, administration of mAb to 
block costimulatory molecule activation can produce harmful side effects such as pruritis, 
urticaria, leucopenia [21, 22], complement-induced neutrophil activation [23] and 
allosensitization to the antibody [24].	  
We have generated peptides derived from human sequences of LFA-1 and ICAM-1 
that block intercellular adhesion and inhibit human T cell function in a mixed lymphocyte 
reaction [25].  These human sequences are conserved in mice and work well in mouse 
assays in vitro.  Here, we explore the hypothesis that use of these peptides in the 
treatment of T1D will induce tolerance to pancreatic auto-antigens.  The non-obese 
diabetic (NOD) mouse is widely used to study T1D [26].  In the present study, our 
peptides were applied to early stage T1D in the NOD mouse model and islet infiltration 
and ability of T cells from treated animals to respond to pancreatic Ag was observed.  
Mechanism of action of the peptides was studied using mouse and human T cells in vitro.  
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Materials and Methods  
Mice  
Female NOD/ShiLtJ and NOD-SCID  (Jackson Laboratories, Bar Harbor,ME) were 
obtained at 8 and 6 weeks of age, respectively, and were housed individually in barrier 
cages.  Animal experiments were performed with approval from the University of Kansas 
Animal Care and Use Committee. 
 
Peptides, chemicals and antibodies.  
Peptides were prepared and cyclized essentially as we have described previously 
[25].  Cyclized peptides were purchased from American Peptide Company, Inc. 
(Sunnyvale, CA).  Lyophilized peptides were stored desiccated at -20oC until use when 
they were resuspended in normal saline at 1µg/µl.  For i.v. injections, 50 µl c-IE-L and 50 
µl cLAB-L, or 50 µl cIE-L and 50 µl c-LBE-L were mixed immediately prior to use.  For 
in vitro experiments, peptides were used at 250 µM each in cell culture RPMI 1640.   
 
Monitoring of diabetes and treatments.  
Blood glucose levels (BGL) were monitored weekly before and after treatment and 
on alternate days during treatment using the OneTouch Ultra 2 glucometer and OneTouch 
Ultra Blue test strips from LifeScan, Inc. (Milpitas, CA).  Mice were fasted 2 h before 
each BGL reading and mouse weight was determined on the same days as BGL 
monitoring.  Saline, control peptides and therapeutic peptides were injected at 48 h 
intervals beginning at 13 weeks of age until 17.5 weeks of age.  Mice were considered 
diabetic after two consecutive BGL readings >250 mg/dL. When severity of disease 
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indicated that mice needed to be terminated, BGL of 600 mg/dL was used thereafter in 
the calculations for those mice.  More than five weeks (39 days) after cessation of 
injections, mice were sacrificed and pancreata and spleens were harvested for further 
analysis. 
 
Splenocyte isolation, cell culture and pancreatic lysates.  
Spleens were harvested from control or peptide treated NOD mice at 23.5 weeks of 
age, minced and repeatedly pressed with a 1cc syringe plunger through a sterile 70 µm 
nylon mesh cell strainer.  Erythrocytes were cleared by a five-minute incubation of the 
cell suspension in ACK lysis buffer (0.15M NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA, 
pH 7.2) at 37oC.  Human T cells were isolated as we have described [27], from peripheral 
blood of healthy donors by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) centrifugation 
followed by E-rosetting.  T cell purity was verified by flow cytometric analysis.   Total 
splenocytes and human T cells were cultured in complete RPMI 1640 (Mediatech, 
Herndon, VA) supplemented with 10% FBS (Atlanta Biologicals, Norcross, GA) as 
described [27].  Pancreatic lysates, used for antigenic stimulation of splenocytes, were 
made from pancreata of healthy NOD mice.  Each pancreas was minced and digested in 
1.1 mg/ml Collagenase P (Roche Diagnostics, Morristown, NJ) in HBSS containing 
10mM HEPES for 15 minutes in a 37oC shaking water bath. The digested material was 
resuspended in normal saline, frozen in liquid N2 for 10 minutes, thawed at 37oC and 
repeated for a total of 3 times to lyse the cells.  
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 Cell stimulation and proliferation assay.  
Splenocytes were stimulated via plate bound antibodies as we have described [7] or 
with 5 µg/ml pancreatic lysates.  Antibodies in PBS were attached to 96 well tissue 
culture plates (Midwest Scientific, St. Louis, MO) by incubation at 37oC for two hours 
and washed three times with PBS before the addition of splenocytes.  Stimulations were 
performed with 0.5 µg/ml anti-CD3ε (clone 500A2).  Human T cell stimulations were 
performed via the same plate bound procedure using 1 µg/ml anti-CD3 (clone OKT3), 10 
µg/ml anti-ICAM-1 (clone R6.5).   All cells were stimulated at a concentration of 2x106 
cells/ml.  For samples cultured with peptides in vitro, cells were incubated with peptides 
in culture medium for 30 minutes prior to stimulation. 
 
Flow cytometry.  
Cell proliferation was measured with CFSE dilution as we have described [7].   
Prior to stimulation, T cells were labeled with 2.5µM 5-(and 6)-Carboxyfluorescein 
diacetate succinimidyl ester (CFSE) from a 5mM stock in DMSO.  Cells were incubated 
for 7 minutes at 37oC in serum-free RPMI 1640.  Cells were labeled for flow cytometry 
by following manufacturer’s instructions of the antibody or reagent used.  Cell apoptosis 
and death was analyzed by AnnexinV and 7-AAD (BD Pharmingen, San Jose, CA).  For 
splenocyte surface protein staining, cells were incubated with CD4-PE (clone RM4-5) 
and CD8-PE-Cy5 (clone 53-6.7) from BD Pharmingen.  Human T cells were stained with 
CD4-APC (clone OKT4) purchased from BioLegend, Inc. (San Diego, CA).  All flow 
cytometry was performed using the Accuri C6 Flow Cytometer and data analysis was 
performed with CFlow (Accuri Cytometers, Inc., Ann Arbor, MI). 
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Pancreas imaging.  
Pancreata were harvested from treated or control mice and frozen for sectioning.  10 
µm planar slices were placed on slides and stained with hematoxylin and eosin (H&E).   
Islets were scored as pre-insulitis, peri-insulitis, intra-insular insulitus or complete islet 
destruction based on Bluestone et al., 2010 [1].  Pancreas sections were photographed at 
20x using a Zeiss Axioscop photomicroscope (Carl Zeiss MicroImaging, LLC, 
Thornwood, NY). 
 
Adoptive Transfer 
 T cells were magnetically isolated from spleens of peptide treated or saline treated 
mice using a total T cell negative selection separation kit (StemCell technologies, 
Vancouver, BC, Canada). 5X105 cells were resuspended in 100 µl of sterile saline and 
injected via tail vein into NOD-SCID mice.  BGL was monitored once a week for 40 
days after adoptive transfer. 
 
Statistical analysis.  
All statistical analysis was performed using GraphPad Prism (GraphPad Software, La 
Jolla, CA.).  Statistical tests and significance for individual figures are indicated in figure 
legends. 
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Results 
Peptides.  
Previous work by others using peptides designed from ICAM-1 demonstrated an 
ability to cause physical inhibition of LFA-1/ICAM-1 interactions [28, 29].  Our group 
designed a series of peptides from ICAM-1 and LFA-1 that inhibited the T cell response 
in a human mixed lymphocyte reaction (MLR) in a dose dependent manner and did not 
affect cell viability [27].  The peptides also were not agonistic in a T cell activation 
response.  From those “parent” 20 amino acid peptides, short 10 amino acid peptides 
were synthesized in a more stable cyclic form as we have described [25].  Selected cyclic 
peptides inhibit T cell adhesion and function in a manner equivalent to the parent 
peptides and also are not toxic to the cells [25].  Table 2.1 describes the cyclic peptides 
used in this study.  cIE-L is derived from the first Ig domain of ICAM-1; cLAB-L is 
synthesized from I-domain of the LFA-1 α-subunit (CD11a); and cLBE-L is derived 
from the LFA-1 β-subunit (CD18).  The therapeutic peptide combination used was cIE-L 
with cLAB-L and the negative peptide combination used was cIE-L with cLBE-L since 
the cyclic LBE-L peptide was not as effective in inhibiting T cell function as its parent 
peptide [25].  
 
Peptide therapy caused a delay in increase of BGL and onset of diabetes.  
Whether the peptides that block ICAM-1 and LFA-1 interactions in vitro could exert an 
effect on TID in mice, was addressed by injecting the peptides into female NOD mice 
beginning at week 13 of age.  Mice were monitored for weight and BGL beginning at 11 
weeks at which time their BGL averaged 90 mg/dL.  By 13 weeks, the average BGL of  
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Table 2.1  
Peptide sequences 
  
Peptide Derivation* Sequence** 
cIE-L a,b ICAM-1 (26-35) DQPKLLGIET 
cLAB-L b LFA-1α (237-246) ITDGEATDSG 
cLBE-L a LFA-1β (112-122) DLSYS-LDDLR 
a Negative peptide combination     b Therapeutic peptide 
combination 
*Numbers represent specific amino acid residues. 
** (-) indicates residue omitted because of synthesis difficulty.  
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all mice had risen to 130 mg/dL so it was concluded that diabetes had begun and the 
study was initiated.  During BGL-matched grouping of mice, seven mice with an average 
BGL of 480 mg/dL, were excluded from the study because their disease had progressed 
well past the stage of early onset which was our target for initiation of therapy.  The 
average BGL of the mice that were placed in the study was 115 mg/dL and it was 
concluded that diabetes in these animals was in the earliest stages of onset.  This was 
supported by the documented initiation of insulitis at 3 to 4 weeks and the decrease in 
pancreatic insulin content that occurs at about 12 weeks of age [30], and by the fact that 
the mice averaged 90 mg/dL at intake. 
 Mice were placed into three equal groups by matching BGL levels, and injected with 
therapeutic peptides (cIE-L+cLAB-L), control peptides (cIE-L+cLBE-L) or saline at 48 h 
intervals; peptides were injected at 50 µg (each) per dose for a total of 100 µg/dose. BGL 
and weight assessments were recorded at the time of injection.  Injections were continued 
for five weeks (17 injections) with the final injection on day 126.  BGL and weight were 
monitored for an additional five weeks, until day 165 (Fig. 2.1).   Mice receiving control 
peptides exhibited elevated BGL starting at 120 days, about 17 weeks of age, followed 
shortly by the saline injected mice. The group receiving therapeutic peptides showed a 
delay in BGL elevation until 145 days, almost three weeks after onset in the controls.  
Incidence of diabetes as defined by two consecutive weekly BGL readings over 250 
mg/dL (Fig. 2.2) also was delayed in the therapeutic peptide treated mice as compared 
with either control group.   No difference was observed in mouse weight among the 
groups (Fig. 2.3).  
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Figure 2.1 
Figure 2.2 
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Figure 2.3 
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Figure 2.1-2.3. Peptide therapy induced a delay in increase of BGL and onset of diabetes.  
2.1) NOD mice were injected on alternate days for five weeks with saline (dashed line), 
control peptides (dotted line) or therapeutic peptides (solid line). Arrows indicate start 
and finish of injections which began in week 13 (91 days of life) and ended in week 18 
after 17 doses had been administered (126 days). Blood glucose levels (BGL) were 
monitored weekly and also on injection days from 11 to 22.5 weeks of age.  Average 
BGL is shown for each group (n = 9 to 11 mice per group).  2.2) Percentages of diabetic 
mice (>250 mg/dL) are shown over time (n = 9 to 11 mice per group).  2.3) Average 
weight in grams over time (n = 9 to 11 mice per group).  Statistical significance was 
determined using one-way ANOVA followed with a Bonferroni correction (A) or using 
Mann-Whitney test (B). *p<0.05, **p<0.01, ***p<0.001.
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Islets in mice treated with therapeutic peptides showed greatly reduced infiltration by 
immune cells.  
The counter receptors ICAM-1 and LFA-1 interact during leukocyte extravasation 
and thus potentially play a role in infiltration of islets in addition to their proposed role in 
T cell signaling. Histological examination of the pancreata was performed to estimate the 
degree of insulitis and leukocyte infiltration present at the end of the experiment.  Five 
weeks after cessation of treatment, pancreata were harvested, paraffin fixed, sectioned 
and stained with hematoxylin and eosin.  Islets were examined and scored for level of 
infiltration (Fig. 2.4, 2.5).  Pancreata from saline injected mice exhibited a high level of 
leukocyte infiltration (Fig. 2.4) compared with therapeutically treated mice (Fig. 2.5).  
The islets found in the tail section of the pancreas were scored for infiltration. 
Eighteen islets were observed in 3 control mice, and 17 islets were observed in 4 
therapeutically treated mice.  Infiltration was almost exclusively by mononuclear cells.  
When scored for level of infiltration (Fig. 2.6), over half the islets from control treated 
mice had been completely infiltrated and another third were classified in the intra-insular 
infiltration category while only 5% scored as pre-insulitis indicating no infiltration.  In 
contrast, the majority (almost 85%) of islets from therapeutic mice showed no infiltration.  
Thus, we conclude that mice treated with the therapeutic peptide combination were 
experiencing greatly reduced leukocyte infiltration at the time the experiment was 
terminated than were the mice treated with control treatments.   
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Figure 2.4 
Figure 2.6	  
Figure 2.5 
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Figure 2.4-2.6. Islets in mice treated with therapeutic peptides showed greatly reduced 
infiltration. 2.4, 2.5) Pancreata were isolated from saline control or therapeutic peptide 
treated mice, and pancreas sections stained with haematoxylin and eosin and scored for 
infiltration using the scoring system described in the materials and methods. 
Representative images are shown.  2.6) Islets were quantified from control and treated 
mice and level of islet infiltration was determined.  (n=18-19 islets per group)
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T cells from peptide treated mice did not respond to islet antigen in a recall response.   
The basic hypothesis under examination was that inhibition of the costimulatory 
events delivered by interaction of the counter receptors LFA-1 and ICAM-1 would lead 
to anergy or death of the antigen reactive T cells.  If the hypothesis were to be supported, 
T cells reactive to pancreatic antigens would be present in the diabetic control mice but 
not in the therapeutically treated animals.   
Splenocytes were harvested five weeks after cessation of therapy.  Total 
splenocytes were stained with CFSE and incubated in culture with 5 µg/ml of pancreatic 
lysate antigen to induce the antigen specific response, or as a negative control, with 
medium alone.  Proliferation of CD4+ and CD8+ T cells was measured after five days in 
culture (Fig. 2.7-2.12).  CD4+ or CD8+ splenocytes from either the saline control mice or 
therapeutically treated mice (Fig. 2.7, 2.7) incubated in the absence of specific antigen 
underwent minimal spontaneous cell division.  CD4+ and CD8+ T cells from saline 
injected mice responded to pancreatic antigen by proliferating (Fig. 2.9), indicating the 
presence of Ag-specific T cells in both the CD4 and CD8 populations.  In contrast, no 
Ag-induced cell division was observed in cells taken from therapeutically treated mice 
(Fig. 2.10) suggesting that the recall response had been eliminated by the in vivo 
treatment with the therapeutic peptides.  In individual experiments, the average increase 
in the number of dividing cells when stimulated with pancreatic antigen compared to 
cells with no stimulation was between 15 and 30 fold with the saline control mice.  This 
was in contrast to no increase with the therapeutic peptide treated mice and this 
difference held true for both CD4+ and CD8+ T cells. 
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Proliferation indices were calculated by dividing the number of proliferating cells 
without antigen stimulation into the number of proliferating cells with antigen stimulation 
minus the number of proliferating cells without antigen; these were plotted for both CD4 
and CD8 cells (Fig. 2.11).  The proliferation index for cells from saline control mice was 
~9 for CD4+ T cells and almost 5 for CD8+ T cells while both indices were 0 for cells 
from therapeutically treated animals.  Fold increase of response by cells from individual 
mice also was plotted for CD4+ and CD8+ cells (Fig. 2.12).  A value of 1 indicates no 
response.  This approach exhibited the same trend of difference between treatment groups 
as did quantifying the average number of dividing cells and the proliferation index.  It is 
also noteworthy that the ability to produce a recall response did not influence blood 
glucose level.  Figure 2.13 diagrams how fold recall would correlate with BGL if the two 
parameters influenced each other in our study.  CD4+ and CD8+ splenocytic recall 
response did not seem to correlate with an elevation in BGL since the mice with the 
highest blood glucose did not necessarily exhibit the greatest recall response as measured 
by fold increase of proliferation with antigen (Fig. 2.14).  It is our hypothesis that this is 
caused by the irregularity of the genetics of the NOD mouse which is spontaneous and 
thought to have greater than 15 mutations, many of them undefined. 
The inability of T cells from therapeutically treated mice to respond to pancreatic 
antigen suggests that the basic hypothesis was upheld and the Ag-responsive T cells were 
either rendered anergic or induced to die in response to the therapeutic peptides.  
However, the possibility that antigen-specific T cells had been induced by the peptide 
therapy to avoid the spleen and home elsewhere could not be formally ruled out by this 
experiment. 
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Correlation of increased BGL with recall response 
Figure 2.14 
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Figure 2.7-2.14. T cells from peptide treated mice did not respond to islet antigen in a 
recall response.  Splenocytes were isolated from mice treated with saline or therapeutic 
peptides and cultured in medium alone or medium plus pancreatic lysate antigen.  
Cellular proliferative recall response was determined using a CFSE dilution proliferation 
assay. Representative flow cytometry histogram plots are shown of CD4+ and CD8+ T 
cell division without pancreatic antigen (2.7 and 2.8) or with antigen (2.9 and 2.10) from 
saline control (2.7 and 2.9) or therapeutic peptide treated (2.8 and 2.10) mice.  2.11) 
Numbers of CD4 and CD8 mouse splenocytes after cell culture without or with antigen of 
cells from saline control (open bars) or therapeutic peptides (filled bars).  2.12) Fold 
change of the response by dividing cells from antigen-stimulated versus nonstimulated 
CD4+ or CD8+ T cells for each control/treatment group. Circles represent saline and 
triangles represent therapeutically treated animals.  2.13) Schematic diagram of fold 
recall and BGL correlation. 2.14) Fold increase of the response by dividing cells from 
antigen-stimulated versus nonstimulated CD4+ or CD8+ T cells compared with final 
BGL of NOD mice.  Data are shown as mean ± SEM (n = 4 to 5 per group).  Statistical 
significance was determined using a Mann-Whitney test. *p<0.05.
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Spleen-derived T cells from treated mice 7 weeks after cessation of therapy show no 
significant difference in proliferation compared to control mice. 
 The lack of recall response in splenocyte T cells five weeks following secession 
of treatment with therapeutic peptides led to an investigation of how long after treatment 
the recall response could be affected.  Mice that received the same therapeutic peptide 
treatment regimen as seen in Figures 2.7-2.12 or control mice that received saline 
injections were left for an additional two weeks and their splenocyte recall response to 
beta cell antigen was measured at seven weeks post therapy cessation.  Proliferating cells 
in medium alone or with added beta cell antigen were quantified and there were no 
significant differences in the number of dividing CD4 and CD8 T cells (Fig. 2.15) or in 
the percent of dividing CD4 and CD8 T cells (Fig. 2.16) with either therapeutically 
treated or control saline mice.  These data suggest that the peptide treatment will delay 
the activation of the autoimmune T cell response for five weeks but the recall response 
might eventually return.   
 
Mouse T cells treated in vitro with peptides did not proliferate in response to mitogenic 
stimulus.  
We also investigated whether a T cell response could be inhibited by exposure to 
therapeutic peptides in vitro immediately before TCR stimulation.  Splenocytes from 
nontreated NOD mice ranging from 10 to 32 weeks of age, at various stages of the 
disease, were tested for effects of the peptides in an in vitro proliferation assay.  The mice 
represented the pre-diabetic stage with BGL of 93, 87, 90; during onset of diabetes with 
BGL of 168, 179, 138; and frankly diabetic with BGL of 437.  Cells were stained with  
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Figure 2.15, 2.16.  Splenocyte T cells from treated mice 7 weeks after cessation of 
therapy show no significant difference in proliferation compared to control mice. 
Splenocytes were isolated from mice treated with saline or therapeutic peptides and 
cultured in medium alone or medium plus pancreatic lysate antigen.  Cellular 
proliferative recall response was determined using a CFSE dilution proliferation assay. 
2.15) Numbers of dividing CD4 and CD8 splenocytes after cell culture without or with 
antigen from saline control (circles) or therapeutic peptides (triangles) injected mice.  
2.16) Percent of dividing CD4 and CD8 splenocytes after cell culture without or with 
antigen from saline control (circles) or therapeutic peptides (triangles) injected mice. 
Data are shown with mean ± SEM (n = 3 per group).  Statistical significance was 
determined using a two-tailed Student’s paired t test. 
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CFSE and pre-incubated in medium alone or in medium plus therapeutic peptides for 
thirty minutes.  Cells were then cultured on plastic dishes coated with anti-CD3 to 
activate effector/memory T cells.   Activation was determined by measuring CFSE 
dilution and cells were co-stained for CD4 or CD8 (Fig. 2.17).  As expected, splenocytes 
left nonstimulated, with (2.3%) or without therapeutic peptides (5.2%) did not proliferate.  
Splenoctyes stimulated through CD3 in medium alone for 7 days proliferated (35.4%) 
whereas splenocytes stimulated through CD3 in the presence of therapeutic peptides did 
not proliferate (3.0%).  Average percent division of stimulated total splenocytes with 
therapeutic peptides was significantly lower than percent division of splenocytes 
stimulated in medium alone and not significantly different from nonstimulated (Fig. 2.18) 
illustrating that the therapeutic peptides were able to inhibit proliferation of immune cells 
taken from healthy mice as well as from mice at early or late stages of disease.  CD4+ 
and CD8+ T cells followed the same proliferation trend as total splenocytes (Fig. 2.19).   
 
Peptide treatment ablated the response response to ICAM-1 costimulation in human T 
cells.  
Although conclusions seemed clear with the mouse model, it was important to examine 
parts of the hypothesis in a human system as well.  As mentioned, LFA-1 serves as a 
costimulatory molecule for T cells [5] and ICAM-1 also acts as a costimulatory molecule 
in human T cells [4].  When stimulated through the TCR plus ICAM-1, cells undergo 
multiple rounds of division, are protected from apoptosis and differentiate into a memory 
phenotype [31].  We investigated whether the therapeutic peptides have the same effect in 
vitro with human T cells as with murine cells by mitogenically stimulating human  
	   53	  
(-
) p
ep
tid
es
 
(+
) p
ep
tid
es
 
 
nonstimulated 
 
anti-CD3 
5.2% 35.4% 
2.3% 3.0% 
 
   (-) peptides 
 
 
   (+) peptides 
 
Figure 2.17 Figure 2.18 
Figure 2.19 
	   54	  
Figure 2.17-2.19. Mouse T cells treated in vitro with peptides did not proliferate in 
response to mitogenic stimulus. Total NOD splenocytes were isolated from nontreated 
animals at various levels of disease progression and left nonstimulated or stimulated with 
plate bound anti-CD3 for 7 days, with or without therapeutic peptides. 2.17) 
Representative histogram plots of total splenic T cell CFSE dilution by nonstimulated and 
stimulated cells in the absence (upper panels) or presence (lower panels) of the peptides.  
2.18) Percent of divided splenic T cells without peptides (open bars) and with peptides 
(closed bars).  2.19) Percent of CD4+ and CD8+ T cells that divided in the absence of 
peptides (open bars) and in the presence of peptides (closed bars). Values are presented 
as mean ± SEM (error bars) and represent data from 7 mice each done in triplicate.  
Statistical significance was determined using two-tailed Student’s paired t test.  
**p<0.01, ***p<0.001.
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peripheral T cells in the presence of the therapeutic peptides. Total T cells were isolated 
from human peripheral blood, stained with CFSE and stimulated with a combination of 
plate bound antibodies against CD3 + ICAM-1 for 5 days as we have done many times 
[4].  Proliferation was determined by CFSE dilution and T cell populations were 
identified with an anti-CD4 co-stain.  Results are presented in both dot plots and a 
histogram representing three separate experiments (Fig. 2.20).   When cultured in 
medium alone, total T cells stimulated through CD3+ICAM-1 proliferated robustly 
(58.5%), undergoing multiple rounds of division (Fig. 2.20 upper left panel), and this 
proliferation was ablated (2.1%) when cells were stimulated in the presence of 
therapeutic peptides (Fig. 2.20, upper right panel).  When the purified T cells were 
stained for CD4, (Fig. 2.20, lower panels), we observed that the CD4+ cells proliferated 
robustly (41%) as did the CD4(-) (CD8+) T cells (17.4%) in response to the stimuli (left 
panel).  In the presence of therapeutic peptides (right panel) neither the CD4+ nor CD8+ 
cells proliferated. 
The average percent (Fig. 2.21) of total (left panel), CD4+ (center panel) and CD8+ 
(right panel) T cells that had undergone division when stimulated in the presence of 
therapeutic peptides was dramatically lower than cells stimulated without peptides. We 
conclude that the peptides were capable of inhibiting T cell activation induced by 
costimulation through CD3+ICAM-1 in human cells. 
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Figure 2.20, 2.21. Peptide treatment ablated the response and increased apoptosis in 
response to ICAM-1 costimulation in human T cells.  Human T cells were isolated from 
peripheral blood and stimulated for five days with plate bound anti-CD3+anti-ICAM-1.  
2.20) Representative histogram plots of CFSE dilution by total T cells (upper panels) and 
dot plots of CFSE dilution (lower panels) of CD4+ and CD8+ [CD4(-)] T cells in the 
absence or presence of the therapeutic peptides.  2.21) Percent of total T cells (left panel), 
CD4+ cells (center panel), or CD8+ cells (right panel) that divided in the absence (open 
bars) or in the presence (closed bars) of therapeutic peptides. Values are presented as 
mean ± SEM (error bars) and represent data from one subject done in triplicate.  
Statistical significance was determined using two-tailed Student’s paired t test.  *p<0.05.
	   58	  
Preliminary data: NOD mice that receive a shorter duration of therapy are still protected 
from T1D up to 11 weeks after cessation of therapy and their splenic T cells do not cause 
T1D when injected into NOD-SCID mice.  
 The ability to achieve a therapeutic response with as few doses as possible is 
desirable from an economic standpoint as well for convenience to the recipient. This led 
us to investigate whether we could achieve the same therapeutic results with seven doses 
administered on alternate days as we observed using the seventeen such doses that were 
used in Figures 2.1-2.14.  This study was done in collaboration with Courtney Gdowski.  
When NOD mice reached an average BGL of 107 mg/dL, mice were placed into two 
equal groups by matching BGL levels, and injected with either therapeutic peptides or 
saline for a series of seven injections that spanned over fourteen days. Mice receiving 
saline injections exhibited elevated BGL starting immediately after the termination of 
injections (Fig. 2.22). The group receiving therapeutic peptides failed to exhibit an 
increase in BGL, even at eleven weeks after peptide treatment was stopped (Fig. 2.22).  
The longevity of the health of the NOD mice receiving therapeutic treatment indicates 
that T1D symptoms were not only delayed, as in Figure 2.1, but also prevented in the 
longer term.  To further determine the any autoreactive capabilities of the T cells from 
mice that received treatment, T cells from treated or saline mice were injected into NOD-
SCID mice and they were observed for symptoms.  NOD-SCID mice are a T cell-
deficient NOD strain, therefore any signs of T1D must be induced by injected 
autoreactive T cells.  T cells were isolated from the spleen of NOD mice nine weeks after 
termination of peptide therapy or saline injections and these cells were injected into 
NOD-SCID mice.  The control mice that received T cells from saline injected mice began 
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to show an increase in BGL 20 days after adoptive transfer and had reached 600mg/dL by 
35 days (Fig. 2.23).  NOD-SCID mice that were injected with T cells taken from 
therapeutically treated mice remained symptom free through 40 days post-adoptive 
transfer (Fig. 2.23).  The adoptive transfer data support our observations of the protection 
from disease after administration of seven therapeutic doses seen in Figure 2.22.   
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Figure 2.22, 2.23.  Preliminary data: NOD mice that receive a shorter duration of therapy 
are still protected from T1D up to 11 weeks after cessation of therapy and their splenic T 
cells do not cause T1D when injected into NOD-SCID mice.  2.22) NOD mice were 
injected on alternate days for two weeks (seven total doses) with saline (dashed line) or 
therapeutic peptides (solid line). Arrows indicate start and finish of injections. Blood 
glucose levels (BGL) were monitored on injection days and then weekly after treatment 
ended.  Average BGL is shown for each group (n = 2-5 mice per time point for each 
group).  2.23) NOD-SCID mice were injected with 5X105 isolated T cells from spleens of 
saline control (dashed line) or therapy injected mice (solid line) from figure 7A. After 
adoptive transfer, blood glucose levels (BGL) were monitored weekly for 40 days.  
Average BGL is shown for each group (n = 2 mice per group).  
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Discussion 
Type-1 diabetes is a T cell driven autoimmune disease that can lead to lifetime 
dependence on insulin as well as disease-related complications that can be very severe 
[32].  Interaction of the adhesion molecule, ICAM-1 with the integrin, LFA-1 likely plays 
an important role in the progression of the disease since ICAM-1 has been shown to be 
expressed at high levels on vascular endothelium, ductal epithelial cells and endothelial 
cells in NOD mouse pancreas and on infiltrating lymphocytes [14, 33, 34].  Since ICAM-
1 is also a costimulatory molecule for T cells it could play a role in T cell activation in 
disease along with T cell migration.  Our previous findings have identified short, cyclic 
peptides that inhibit ICAM-1:LFA-1 interactions, thereby arresting T cell activation [27].  
In the present study, we examined the ability of our ICAM-1- and LFA-1-derived 
peptides to reduce the severity of T1D in the NOD mouse model and the mechanism by 
which this might happen. 
As mentioned, costimulatory blockade has been examined by other investigators for 
treatment of diabetes and other autoimmune diseases.  In one example, use of CTLA4Ig 
(which binds to B7 molecules on antigen presenting cells) and anti-B7.2 to interfere with 
the CD28/B7 pathway during the development of diabetes, inhibited the disease when 
administered at 2-4 weeks of age but not after 10 weeks in NOD mice [17].   Also, this 
therapy did not inhibit insulitis at any stage of administration; but treatment with anti-
B7.1 actually accelerated the disease [17].  Inhibiting the CD40/CD40L interaction also 
ablates the disease in NOD mice when administered at 3 weeks of age but not after 9 
weeks and the mechanism is not via a regulatory T cell pathway [18].  Blocking multiple 
costimulatory pathways does provide more efficient treatment of T1D in a mouse model 
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than blockade of a single costimulatory pathway.  The combination of monoclonal 
antibodies against ICOS and CD40L significantly diminished disease in NOD mice 
compared with blockade of either pathway alone even when the treatment was given at 
10 weeks of age [19].  Previous work with ICAM-1/LFA-1 blockade was conducted with 
monoclonal antibodies and reduced symptoms of T1D [13].  This was attributed to the 
inability of lymphocytes to enter islets, and was not considered to be due to a lymphocyte 
functional impairment.  Our present data suggest that blocking the LFA-1/ICAM-1 
interaction with our short cyclic peptides inhibits both T cell localization and T cell 
function. 
When administered to NOD mice that had begun to undergo insulitis and 
experience elevated BGL, the therapeutic peptides were able to delay onset of diabetes by 
3 to 4 weeks (from ~day 120 until day 145) as measured by blood glucose level 
compared to saline or control peptides.  In addition, some of the mice that were not 
treated with therapeutic peptides did not survive until the conclusion of observations.  
The control mice began to show symptoms before cessation of injections whereas the 
therapeutically treated mice avoided symptoms for an additional three weeks.  This delay 
also was evident when quantifying the percent of control versus therapeutically treated 
mice that are considered to be diabetic based on BGL.   
The ICAM-1:LFA-1 interaction is important for autoreactive T cells to migrate into 
the pancreas and initiate β cell destruction [13, 14, 35].  Mice were sacrificed and organs 
harvested at day 165 of the experiment which is 5.6 weeks after injections were 
discontinued.  Pancreata from therapeutic peptide treated mice showed much less 
infiltration compared with islets from saline treated mice which were highly infiltrated.  
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From the in vivo experiments, it formally remains unclear whether the autoreactive T 
cells were inactivated by the peptides in vivo or had been induced to migrate to a different 
location or not migrate at all.  Islet specific T cell clones have been established from 
spleens of NOD mice [36, 37], suggesting that antigen-specific responses in the spleen 
are representative of the T cell response in T1D.  To test this in our system, we examined 
spenocytes from our treated and control mice for islet-antigen-specific reactivity.  
Splenocytes isolated from saline control mice specifically responded to β cell antigen 
whereas splenocytes from therapeutically treated mice did not activate in the presence of 
specific antigen.  This suggests that the therapeutic peptides rendered the mixed T cell 
population unable to respond to pancreatic antigens.  Splenocytes from untreated NOD 
mice exhibiting varied levels of disease also did not respond to TCR stimulation when 
incubated with therapeutic peptides in vitro. 
Our data suggest that the therapeutic peptides inactivated the T cell component of 
T1D, however, the mice still eventually did develop symptoms in the 17 dose experiment.  
One possibility is that the therapy was initiated too late after onset of insulitis.  In these 
mice, insulitis begins around five weeks of age [26]. As early as three weeks of age 
dendritic cells and macrophages are found in insulitic infiltrates and thought to drive 
early autoreactive responses [38-40]. It is conceivable that islet destruction was too 
advanced for recovery from symptoms even though the therapy stopped infiltration and 
diminished T cell response.  Also, insulin autoantibodies can reach peak levels in 
prediabetic mice, well before the onset of symptoms and elevated BGL [41, 42]. 
Although T1D is a T cell driven disease, insulin autoantibodies are a contributing factor 
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to disease progression and would have begun to be produced at elevated levels by the 
time of administration of the therapeutic peptides.   
Introduction into a C57BL/6 background of an MHC haplotype known to be 
involved in development of T1D in NOD mice did not lead to disease [43]; hence, MHC 
autoreactivity alone is insufficient to induce T1D.  This suggests that multiple genetic 
components are involved and even if some of the immune components can be diminished 
in the NOD mouse, disease progression may continue based on other predisposing 
genetic factors.  The use of the NOD mouse model for T1D has many advantages when 
examining the immune reaction due to its similarity to the human immune process of 
disease [44], however, the usefulness of the model has come into question [45-47] and an 
alternative animal model as well as additional in vitro human studies with the therapeutic 
peptides are required. 
 Taken together, the data presented here suggest that peptide blockade of LFA-
1:ICAM-1 interactions in NOD mice experiencing onset of diabetes could delay onset of 
symptoms.  The delay was achieved by a mechanism that inhibited infiltration into the 
pancreas as well as eliminating T cells with reactivity to pancreatic antigens.  In vitro, the 
peptides inhibited activation of both murine and human T cells that were under a 
mitogenic stimulus. The accumulated data suggest that a combination of LFA-1 and 
ICAM-1 blocking peptides may potentially provide a useful therapeutic model for 
autoimmune disease and organ transplantation. 
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Chapter 3 
Early development of a memory T cell phenotype with costimulation through 
ICAM-1 that is not influenced by additional costimulation 
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Introduction 
 
 Immunological memory is a defining characteristic of the adaptive immune 
system.  Memory T cells are an essential component of the immune response because 
they can provide long-term protection against foreign antigens, activate rapidly into 
effector cells following secondary stimulus and require less signal than naïve T cells to 
become activated.  CD4+ memory T cells are especially important because they confer 
longer immunological protection than antibody or CD8+ memory cells (1,2) and are 
essential for initiating secondary B cell and cytotoxic T cell responses.   
 CD4+ memory T cells exhibit multiple protective functions in the body.  After 
activation, resting memory cells begin to produce effector cytokines within hours, 
whereas naïve cells require days to activate in response to antigen (3,4).  Activated 
memory T cells can rapidly secrete proinflammatory cytokines and chemokines to recruit 
leukocytes to sites of inflammation and initiate the innate immune response much quicker 
than naïve cells (5,6). Activated CD4+ T cells influence the adaptive immune response 
by producing Th1 cytokines to initiate the cytotoxic T cell response or by producing Th2 
cytokines and expressing additional cell surface molecules such as CD40L to activate the 
humoral response (7-9).  The secondary T helper response generated from memory cells 
is superior to the primary effector response from naïve cells due primarily to the prompt 
nature of the response as well as the ability to produce more effector molecules (10).  
This is demonstrated, in part, by the fact that secondary effector CD4+ T cells could 
protect mice from influenza better than primary effectors without antiviral CD8+ T cell 
or B cell components (11). 
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 Memory T cells can be defined as CD45RO+, CDlla+ and CD27(-) (12).  Central 
memory T cells (TCM) also express CCR7 and CD62L, which allow the cells to circulate 
into the peripheral lymph nodes (PLNs) for immunosurveillance (13).  While IL-15 is 
necessary for CD8+ memory cell survival, IL-7 and TCR:MHC II engagement are more 
important for CD4+ memory cell generation, survival and homeostasis (14-19).  Memory 
cells have less strict requirements for activation compared to naïve cells. Lower doses of 
antigen, reduced levels of costimulation and/or shorter duration of signal is needed for 
memory T cells to activate than naïve (20,21).  Upon reactivation, CD4+ memory T cells 
can alter their effector response (depending on TCR stimulus) from its initial effector 
response and this functional plasticity is thought to have multiple advantages in 
adjustment of the immune response (22).   
 When CD4+ naïve T cells encounter their cognate antigen in a primary immune 
response, they undergo proliferation and differentiation into effector cells with 
specialized functions (23).  The effector population is short lived and eventually dies by 
apoptosis leaving only the memory phenotype.  The progression to a memory cell 
phenotype is proposed to happen in one of two ways.  The theory of linear progression 
supports that memory cells are generated from effector precursors whereas the proposed 
divergent pathway indicates that the memory population emerges in parallel with the 
effector population from a predestined precursor (24-26).  The pathway that a 
differentiating T cell takes from naïve to memory can be influenced by many factors and 
may differ depending on how the naïve T cell is signaled. Factors that have been found to 
influence memory cell development include: precursor frequency, TCR affinity, antigen 
dose, antigen duration, cytokines and costimulation (10).  It has been suggested that since 
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relatively few signals are needed for effector-to-memory transition after optimal priming 
of naïve CD4+ T cells, the memory cell fate is determined early in activation (10).  This 
concept is supported by a rapid effector-to-memory transition observed when memory 
phenotype cells are seen after primed effector cells were rested only three days in vitro 
and away from antigen (27,28).    
 Differences in the outcomes of activation and differentiation of T cells with 
various costimulatory molecules indicates the importance of costimulation in the 
progression of CD4+ naïve T cells to an effector or memory phenotype.  Of the 
costimulatory molecules that are on the surface of CD4+ naïve T cells, CD28 and ICAM-
1 have been shown to generate phenotypic and functional memory populations (29). 
Costimulation through CD28 or ICAM-1 both lead to proliferation, IL-2 production and 
protection from apoptosis, however, they differ in their outcomes in that CD28 will 
generate both Th1 and Th2 subsets while ICAM-1 generates a Th1 population (29).   
 The mechanisms of memory cell generation and the factors that regulate their 
development are not fully understood and some of the aspects are still being elucidated.  
This chapter will examine the kinetics of differentiation of CD4+ naïve cells, the 
minimum stimulation required to achieve a memory cell phenotype, and whether 
differentiation can be modulated when signals change after initial activation.  Our goal is 
to provide some insight to how quickly memory cells develop from naïve cells and 
whether memory T cells arise from effector cells or are induced from a naïve precursor.  
We also will examine the differences in activation and memory cell development with 
costimulation through ICAM-1 or CD28 and ask whether removing one signal or 
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exchanging it will alter the end population.  With this approach, we hope to help 
elucidate the presence of a precursor population following initial signal.    
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Materials and methods 
Antibodies and Reagents 
Anti-CD54 (R6.5D6) was purchased from BioXCell (West Lebanon, NH), anti-CD28 
(clone ANC28.1) was purchased from Ancell (Minneapolis, MN) and anti-CD3 (OKT3) 
was purchased from eBioscience (San Diego, CA). Anti-CD11a-FITC, anti-CD27-PE, 
anti-CD45RA-FITC and anti-CD45RO-TriColor were purchased from Caltag 
Laboratories (Burlingame, CA).  
 
Cell Purification 
Naïve human CD4+ T cells were isolated from peripheral blood of multiple donors by 
negative selection using a naïve T cell enrichment kit (Stem Cell Technologies, 
Vancouver, BC, Canada).  All magnetically selected naïve CD4+ T cell populations were 
of >98% purity as assessed by flow cytometry (30).  In the present work, purified naïve 
human T cells represents cells that are CD4(+) CD45RA(+)RO(-) CD11alo CD27(+).  
 
T cell Stimulation 
Antibodies in PBS were attached to tissue culture-treated plates (Midwest Scientific, St. 
Louis, MO) by incubation at 37°C for 2 hours or overnight at 4°C, and wells were 
washed three times with PBS to remove unbound antibody.  Naïve CD4+ T cells were 
added at a concentration of 1x106-2×106 / ml, and stimulated with 1 µg/ml anti-CD3 plus 
10 µg/ml anti-ICAM-1, or 5 µg / ml anti-CD28.  For experiments in which cells were 
removed from stimulation or switched to new stimulation, cells were pippetted using a 
1000ul pipette and tip to minimize cell damage and then transferred to a clean well or a 
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new well with freshly attached stimulating antibodies, respectively.  Optimal antibody 
concentrations were determined based on the minimum dose that led to maximum T cell 
proliferation (not shown).   
 
Flow Cytometry 
Flow cytometry was performed using the FACScan (Becton Dickenson, San Jose CA) or 
the Accuri C6 Flow Cytometer System (Accuri Cytomoters, Ann Arbor MI).  The 
FACScan was calibrated using CaliBRITE beads (Becton Dickinson), and the Accuri C6 
was calibrated using Sphero APC Calibration Particles (Spherotech, Inc. Lake Forest, 
IL).  This was supplemented by compensation using singly stained cells.  Data were 
analyzed using Cell Quest (Becton Dickenson), FlowJo (Tree Star Inc, Ashland, OR) and 
CFlow (Accuri Cytometers). 
 
Luminex Assay 
Cell culture supernatants were collected at 1, 3, 5, 7, 10, 14 and 21 days following 
stimulation.  25 plex human cytokine panel luminex (LHC0009) was purchased from 
Biosource.  Samples were diluted 1:1 and assay was performed according to 
manufacturer’s protocol.  Samples were analyzed with the Luminex100 multiplex system 
and xPONENT® software. 
 
 
 
 
	   80	  
Statistical analysis. 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA.) or SigmaStat (Systat Software Inc. San Jose, CA).  Statistical tests and significance 
for individual figures are indicated in figure legends. 
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Results 
 
Costimulation through ICAM-1 induces naïve T cell differentiation to a memory 
phenotype but delays induction of CD45R0 expression compared to CD28 
 CD45 is a protein tyrosine phosphatase belonging to the common leukocyte 
antigen family and is required for T cell receptor signal transduction (31, 32).  CD45 is 
expressed as different isoforms on T cells, and as naïve T cells become activated they 
lose expression of the CD45RA isoform and express a CD45RO isoform (33).  Our lab 
has shown that costimulation through ICAM-1 leads to production of a memory 
phenotype after 12-14 days of stimulation.  We investigated the rate at which naïve T 
cells began to downregulate CD45RA and upregulate CD45RO expression to indicate 
cell differentiation and if that change varied with costimulation through ICAM-1 or 
CD28.  Five days after costimulation through ICAM-1, CD4+ T cells remained mostly 
CD45RA+ (76%) and only a small fraction of the cells had progressed to single positive 
CD45RO+ (4%) leaving the rest of the cells in a transitional CD45RA(+)CD45RO(+) 
stage of differentiation (Fig. 3.1).  Day 7 showed that 53% of cells costimulated through 
ICAM-1 were still CD45RA+ and 24% were CD45RO+, however, by day 11 only 21% 
of cell expressed CD45RA and 60% expresses CD45RO indicative of rapid 
differentiation after day 7 (Fig. 3.1).  When CD4+ naïve T cells were costimulated 
through CD28 for five days, the percent of CD45RA had dropped to 47% but the 
population expressing CD45RO was only 21% indicating a transitional population of 
double positive cells (Fig. 3.1).  By day 7, 38% of cells costimulated through CD28  
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Figure 3.1 
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Figure 3.1.  Costimulation through ICAM-1 induces naïve T cell differentiation to a 
memory phenotype but delays induction of CD45R0 expression compared to CD28. 
Percent CD45RA positive of isolated CD4+ naïve T cells at day 0 was determined by 
flow cytometry.  Naïve cells were stimulated through CD3+ICAM-1 or CD3+CD28 for 
5, 7, or 11 days. Expression of CD45RA vs. CD45RO was determined by flow 
cytometry.  n=3.
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expressed CD45RA with 42% expressing CD45RO and the remaining cells were double 
positive (Fig. 3.1).  After 11 days of CD28 costimulation, 33% of cells expressed  
CD45RA and 53% expressed CD45RO, indicating a progressive decrease in 
CD45RA+CD45RO(-) and CD45RA(+)CD45RO(+) transitional cells after the day 5 time 
point (Fig. 3.1).  Together, these data suggest that costimulation of CD4+ naïve T cells 
through CD28 initiates activation quicker than ICAM-1 with over half of the cells being 
positive for CD45RO or double positive for CD45RA/RO by day five and which is 
similar to what is seen with costimulation through ICAM-1 at day 7.  However, the cells 
costimulated through ICAM-1 quickly caught up to CD28 between days 7 and 11 
exhibiting population of CD45RO positive cells even greater than CD28 at day 11.   
 
During long term costimulation of naïve human T cells through ICAM-1, memory T cells 
appear by days 5 - 7  
 Previous depictions of the rapid nature by which effector cells can transition to 
memory were described using in vitro or in vivo primed effector cells that exhibited a 
memory phenotype shortly following antigen clearance in vivo or after 3 days of rest in 
vitro (27,28).  The efficiency of memory cell generation shown by other groups led us to 
question the timeframe in which memory T cells were able to differentiate from naïve 
cell activation using our in vitro stimulation protocol.  We also wanted to examine any 
differences in the time it took to differentiate naïve T cells to effector and memory when 
costimulated through ICAM-1 or CD28, given the differences we observed in CD45RO 
expression.  CD4+ naïve T cells were stimulated in vitro for 3, 5, 7, and 12 days.  Figure 
3.2 illustrates the kinetics of progression from the naïve phenotype [CD27(+)CD11a(-) 
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(upper left quadrant)] to effector cells [CD27(+)CD11a(+) (upper right quadrant)] and a 
memory phenotype [CD27(-)CD11a(+) (lower right quadrant)].  Costimulation of CD4+ 
naïve T cells through ICAM-1 or CD28 leads to the apperance of effector cells after 3 
days of stimulation and we begin to see cells displaying a memory phenotype as rapidly 
as 5 days after stimulation (Fig. 3.2).  The number of effector and memory cells at each 
time point were quantified.  As expected, effector cell numbers were at their highest 
between 5 and 7 days after costimulation through either ICAM-1 or CD28, contracting to 
far fewer cells by day 12 (Fig. 3.3).   Cells that were costimulated through ICAM-1 
began to exhibit detectable memory T cell numbers at 5 days of stimulation with robust 
cell numbers appearing at 7 and 12 days of stimulation (Fig. 3.4).  Costimulation of 
CD4+ naïve T cells through CD28 generated more memory cells than ICAM-1 at day 5 
of stimulation and those cell numbers plateau to 7 and 12 days of stimulation (Fig. 3.4).  
Examining the data together, we can observe that costimulation through ICAM-1 
produces more robust activation and differentiation compared to CD28, giving a greater 
number of effector cells at each day of stimulation and far more memory cells by days 7 
and 12.  The efficiency of differentiation with ICAM-1 is interesting considering the 
delay in CD45RO expression we observed in figure 1.1.  Also, the appearance of a 
memory phenotype by 5-7 days of stimulation through either ICAM-1 or CD28 is far 
earlier than expected.   This observation may be supportive of a precursor memory 
population or the hypothesis that weak signal after initial stimulation is required for 
differentiation.   
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Figure 3.4 
Figure 3.3 
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Figure 3.2-3.4.  During long term costimulation of naïve human T cells through ICAM-1, 
memory T cells appear by days 5 – 7.  Naïve cells were stimulated through CD3+ICAM-
1 or CD3+CD28 for 3, 5, 7 and 12 days. Figure 3.2) Cell phenotype was assessed by 
CD11a and CD27 expression to be naïve (CD11alo, CD27+), effector (CD11a+, CD27+) 
or memory (CD11a+, CD27lo) by flow cytometry.  Figure 3.3, 3.4)  Total number of 
effector cells (3.3) or memory cells (3.4) was determined by CFlow software. Data are 
presented as mean ± SEM, *p<0.05, **p<0.01 using paired two tailed t-Test.  n=4. 
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Costimulation of naïve T cells through ICAM-1, when interrupted before days 5 - 7 leads 
to reduced memory cell differentiation compared with continuous costimulation 
 Since we see memory cells develop early after costimulation through ICAM-1 or 
CD28, we wanted to determine if a memory fate was set early after stimulation or if more 
continual stimulation was needed.  CD4+ naïve T cells were stimulated for 1, 3, 5, 7, and 
10 days before they were removed from stimulating antibodies and transferred to a clean 
96 well plate where they remained with no additional stimulation until 12 total days 
following initial stimulation before being analyzed for phenotype (Fig. 3.5).  When 
CD4+ naïve T cells costimulated through ICAM-1 were removed from stimulating 
antibodies after one day (D1), we did not see activation or differentiation of cells at day 
12 indicated by a mostly naïve phenotype (Fig. 3.6) and very low effector cell numbers 
(Fig. 3.7).   Cells taken off CD3+ICAM-1 stimulatory antibodies at day 3 (D3) or 5 (D5) 
did exhibit some differentiation but were slightly impaired in activation to an effector 
phenotype by day 12 (Fig. 3.6) and number of effector cells (Fig. 3.7) compared to cells 
not removed from stimulation.  Cells that had been costimulated through ICAM-1 for 7 
days before resting to day 12 exhibited differentiation to an effector phenotype that 
resembled cells not removed from stimulus (Fig. 3.6), as well, they produced numbers of 
effector cells that were not significantly different from the day 12-14 cells (Fig. 3.7).  
When examining the differentiation of CD4+ naïve T cells to a memory phenotype after 
costimulation through ICAM-1 for various days, we see that a very small memory 
population does develop after 1, 3 or 5 days of stimulation before resting with more 
defined memory populations generated at 7 days of stimulation (Fig. 3.6), however these 
populations are not reflected when looking at total memory cell numbers (Fig. 3.8).  
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Costimulation of CD4+ naïve T cells through ICAM-1 for 1 to 7 days before resting 
produced memory cells numbers that were significantly different than the number of 
memory cells after 12-14 days of constant stimulation (Fig. 3.8) indicating a considerably 
more favorable memory cell expansion occurred with constant ICAM-1 costimulation.   
 To compare the duration of costimulation needed for activation by ICAM-1, we 
applied the same stimulation parameters to CD28.  Costimulation of CD4+ naïve T cells 
through CD28 for 1 or 3 days prior to interruption did initiate a small amount of 
activation, as we can observe an effector phenotype beginning to emerge from naïve cells 
(Fig 3.9) but the number of effector cells is significantly different from cells left on 
continual stimulation (Fig. 3.10).  However, unlike costimulation through ICAM-1, at 5 
days of costimulation through CD28 before rest a more substantial effector population is 
observable in phenotype (Fig. 3.9) as well as cell number (Fig. 3.10).  By 7 days of 
costimulation through CD28, the differentiation to an effector phenotype (Fig. 3.9) and 
activation to produce a sizable number of differentiated cells (Fig. 3.10) closely 
resembles that of cells that were left on stimulation for 12-14 days.  When examining 
memory cell generation with short-term costimulation through CD28 (Fig. 3.11), we see 
that much like ICAM-1 a small but noticeable memory phenotype develops after just one 
day of stimulation (Fig. 3.9).  However, memory cell numbers do not resemble those of 
constantly stimulated cells until after 5 days of stimulation (Fig. 3.11).  As a control, the 
same procedures were applied to stimulation through the TCR (CD3) alone, which should 
not be able to induce full activation/differentiation of naïve cells.  As expected, 
stimulation through CD3 did not activate or differentiate cells to an effector or memory 
phenotype (Fig. 3.12, 3.13). 
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Figure 3.5 
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Figure 3.6 
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Figure 3.9 
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Figure 3.5-3.13.  Costimulation of naïve T cells through ICAM-1, when truncated before 
days 5 - 7 leads to reduced memory cell differentiation compared with continuous 
costimulation. Naïve cells were stimulated through CD3 alone, CD3+ICAM-1 or 
CD3+CD28 for 1, 3, 5 or 7 days before being removed from stimulation until day 12-14 
or left on constant stimulation for 12-14 days.  12-14 days were used interchangeably 
with identical results.    Figure 3.5) Schematic of the duration of stimulation or rest for 
each time point.  Figures 3.6, 3.9) Cell phenotype was assessed by CD11a and CD27 
expression to be naïve (CD11alo, CD27+), effector (CD11a+, CD27+) or memory 
(CD11a+, CD27lo) by flow cytometry. Figures 3.7, 3.8, 3.10, 3.11, 3.12, 3.13)  Total 
number of effector cells (3.7, 3.10, 3.12) or memory cells (3.8, 3.11, 3.13) was 
determined by CFlow software. Samples were tested for significance with day 12-14 
effector or memory cell numbers.  Data are presented as mean ± SEM, *p<0.05, 
**p<0.01 using paired two tailed t-Test.  CD3+ICAM-1: day 1 n=7; days 3, 5, 7 n=11; 
day 12-14 n=10.  CD3+CD28: day 1 n=8; days 3, 5, 7 n=12; day 12-14 n=11.  CD3: day 
1 n=3; days 3, 5, 7 n=6; day 12-14 n=5.
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 Although it seems that CD4+ naïve T cells costimulated through ICAM-1 needed 
longer stimulation than costimulation through CD28 to develop differentiated cells, the 
total number of differentiated cells with constant ICAM-1 stimulation was so much 
higher than CD28 that the effector and memory cell numbers from interrupted stimulation 
through ICAM-1 are very similar, if not greater, when compared to that of CD28.  It is 
also interesting that the early interrupted stimulation of ICAM-1 or CD28 led to a small 
subpopulation of cells that differentiated to memory phenotype even in the absence of 
effector cell production (Fig. 3.6 and 3.9, days 1 and 3).  The memory phenotype seems 
to originate from a CD11a, CD27 double negative population and not an effector 
population. This phenomenon was observed to various degrees in flow cytometry dot 
plots from multiple subjects.  It is possible that the small memory population developed 
from precursors that needed brief stimulation and little, if any, proliferation to 
differentiate.    
  
The effects observed with using interruption costimulation through ICAM-1 or CD28 
were due to removal of stimulus, not disruption of cell culture  
 To verify that the differentiation results seen in Figures 3.6-3.11 were from 
truncation of signal and not simply an artifact of disrupting the cells in culture we 
mimicked the removal procedure of cells from stimulating antibodies while leaving the 
cells on continual stimulating antibodies.   CD4+ naïve T cells were costimulated through 
ICAM-1 or CD28 and at 1, 3, 5, or 7 days after initial stimulation, cells were mixed by 
pipetting but left in the stimulating well for the remainder of the 12 days and analyzed for 
phenotype.  Cells that were mixed in culture at various time points following 
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costimulation through ICAM-1 or CD28 displayed a very similar differentiation pattern 
of CD11a and CD27 expression as cells that were stimuated undisturbed for 12 days (Fig. 
3.14).   As well, the number of resulting memory cells was not statistically different with 
cells mixed at each time point or stimulated for 12 day without disruption for either 
ICAM-1 or CD28 (Fig. 3.15, 3.16).  This indicates that the reduction in memory cells 
seen with early interruption of stimulus in Figures 3.6-3.11 was due to the removal from 
signal and not simply disruption of cells in culture.   
 
Change of costimulatory signal does not modulate differentiation to a memory phenotype 
at various times following initial costimulation through ICAM-1 or CD28 
 Our system of in vitro stimulation allows for the elimination of variables by 
isolating initial signals being sent into cells. This permits us to effectively observe the 
effect that each individual costimulatory signal has on activation and differentiation of 
the cell.   However, during an immune response in vivo it is less likely that T cells receive 
only one costimulatory signal.  In this section, we examine the effect that multiple 
costimulatory signals have on differentiation of naïve T cells.  Specifically, we wanted to 
see if switching the costimulatory signal at different times after initial costimulation 
would have any impact on memory phenotype generation.  The goal is to determine 
whether we can modulate the effect of stimulation during the activation process or if the 
initial stimulus determines fate of the cell.  Figure 3.17 depicts the stimulation switching 
system used.  Naïve CD4+ T cells were initially stimulated through CD3 alone, 
CD3+ICAM-1 or CD3+CD28.  At 1, 3, 5 and 7 days after stimulation, cells were 
removed from stimulation completely as a control or transferred to a single stimulus of  
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Figure 3.14 
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Figure 3.15 
	  
Figure 3.16 
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Figure 3.14-3.16. The effects observed with interruption of costimulation through ICAM-
1 or CD28 were due to removal of stimulus, not mechanical disruption of cell culture.  As 
a control, cells were mixed in culture at days 1, 3, 5 and 7 to mimic cell transfer and left 
to rest in the same well as primary stimulation until day 12.  Figure 3.14) Cell phenotype 
was assessed by CD11a and CD27 expression to be naïve (CD11alo, CD27+), effector 
(CD11a+, CD27+) or memory (CD11a+, CD27lo) by flow cytometry. Figure 3.15, 3.16)  
Total number of memory cells costimulated through ICAM-1 (3.15) or CD28 (3.16) was 
determined by CFlow software. All samples were tested for significance with day 12 
memory cell numbers.  Data are presented as mean ± SEM, significance was assessed 
using paired two tailed t-Test.  n=4
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either CD3, ICAM-1, CD28 where they would remain for 14 total days of stimulation.  
When naïve cells were initially costimulated through CD3+ICAM-1 and transferred to 
CD3, ICAM-1 or CD28 at day 1, 3, 5, or 7 the number of cells displaying a memory 
phenotype was not modulated compared to the control of cells taken off of stimulating 
antibodies altogether (Fig. 3.18).  Also, cells that received only signal 1, CD3, for 1, 3, 5 
or 7 days before getting ICAM-1 costimulation did not produce significant memory cells 
numbers.  This indicates that after naïve CD4+ T cells receive initial stimulation through 
CD3+ICAM-1, they are not easily modulated by or cannot receive additional 
costimulation from another legitimate costimulatory receptor such as CD28.  These data 
could argue for early determination of cell fate for a small population of naïve cells as 
well as need for constant costimulation for efficient memory cell production of cells 
costimulated through ICAM-1. One exception was observed when cells stimulated 
through CD3+ICAM-1 were transferred to additional CD3 at day 7 of initial stimulation 
(Fig. 3.18).  It is interesting that cells could be modulated so late after stimulation, 
however, it could be conceivable that the high number of effector cells seen at 7 days 
following stimulation through CD3+ICAM-1 (Fig. 3.3) were able to receive additional 
signal 1 to further propagate cell differentiation. 
 When CD4+ naïve T cells were initially stimulated through CD3+CD28 before 
switching costimulatory signals at days 1, 3, 5 or 7, we observed a slightly different 
pattern of memory cell numbers compared with CD3+ICAM-1.  The majority of 
stimulation treatments in figure 3.19 did not show a statistically significant difference 
from cells that were continuously costimulated through CD28.  Much like in figure 3.11 
we can assume that this is because of the lower total number of memory cells generated  
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Figure 3.17 
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Figure 3.18 
	   106	  
Figure 3.19 
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Figures 3.17-3.19.  Change of costimulatory signal does not modulate differentiation to a 
memory phenotype at various times following initial costimulation through ICAM-1 or 
CD28. Figure 3.17) Schematic of the stimulation transfer procedure. Figure 3.18)  
Number of memory cells generated with stimulation through CD3+ICAM-1 before 
transfer to indicated stimulation or removal from stimulation at days 1, 3, 5 or 7.  
Memory cell number was analyzed at day 14. Figure 3.19)  Number of memory cells 
generated with stimulation through CD3+CD28 before transfer to indicated stimulation 
or removal from stimulation at days 1, 3, 5 or 7.  All memory cell numbers were analyzed 
at day 14. All samples were tested for significance with day 14 memory cell numbers.  
Data are presented as mean ± SEM, *p<0.05, **p<0.01 and no asterisk indicates no 
significant difference to day 14 using paired two tailed t-Test. CD3+ICAM-1: n=3-4.  
CD3+CD28:n=4-5. 
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by constant costimulation through CD28 compared to constant costimulation through 
ICAM-1 for 12-14 days.  Much like in figure 3.18, naïve cells that were initially 
costimulated through CD3+CD28 and transferred to CD3, ICAM-1 or CD28 (or switched 
from CD3 alone to CD28) at any time point did not differ in the number of cells 
displaying a memory phenotype compared to the control activity of cells removed from 
stimulating antibodies altogether (Fig. 3.19).  One trend of interest is that at early transfer 
times (days 1, 3, and 5), cells that go from CD3+CD28 to CD3 alone exhibit a greater 
memory cell number than other stimulation treatments (Fig. 3.19).  This observation 
could support the hypothesis that duration of antigen signal can influence differentiation 
and memory cell development (21,22).    
 
Preliminary data: Costimulation of CD4+ naïve T cells through ICAM-1 or CD28 
induces the generation memory cells in the presence of effector cytokines.  
 Previous studies have indicated that the switch from effector to memory T cells 
happens rapidly in the absence of antigen and effector cytokines (27, 34, 35).  We have 
observed that in our in vitro stimulation system, we do not observe creation of a 
substantial memory population after removal from stimulation (Fig. 3.6-3.11), therefore 
we looked at the cell culture supernatants to determine effector cytokine presence during 
differentiation of naïve T cells following costimulation through ICAM-1 or CD28.  All of 
the cytokine profiling was done in collaboration with Kelli Williams in the Benedict lab.  
Pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α, were present in culture during 
effector and memory stages of differentiation (days 7-21) (Fig. 3.20).  Th1 effector 
cytokines IFN-γ and IL-12 but not IL-2 were abundant during differentation stages (Fig. 
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3.21), as well, Th2 cytokines IL-4, IL-5 and IL-10 were all detected in various amounts at 
effector and memory development phases (days 7-21) (Fig. 3.22).  Our preliminary 
findings suggest that we can develop large numbers of memory phenotype cells with 
constant costimulation through ICAM-1 without the removal of inflammatory or effector 
cytokines. 
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Figure 3.20 
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Figures 3.20-3.22.  Preliminary data: Costimulation of CD4+ naïve T cells through 
ICAM-1 or CD28 induces the generation memory cells in the presence of effector 
cytokines. Cell culture supernatants were analyzed at days 1, 3, 5, 7, 10, 14 and 21 for the 
presence of inflammatory cytokines (3.20), Th1 cytokines (3.21) and Th2 cytokines 
(3.22).  NS= nonstimulated.  n=1.
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Discussion 
 Upon antigenic stimulation, naïve T cells undergo clonal expansion that leads to 
the apperance of an effector cell population followed by clonal contraction.  The resulting 
cell phenotype is a highly differentiated memory population.  CD4+ memory T cells are 
an extremely important part of the immune response because they allow the body to 
induce an immune reaction days before a primary response would be able to take effect.  
Memory cells can signal to activate the innate and other arms of the adaptive immune 
response in the same amount of time that takes naïve cells to begin expansion because 
memory cells require weaker antigenic dose and shorter duration for activation (3, 4, 10).  
The specific factors required for efficient memory cell generation remain unclear and the 
ability to define those parameters could provide useful tools for disease treatment and 
modulation of the immune response.  Here we aim to define the duration of stimulation 
needed for differentiation of CD4+ naïve T cells into memory and the degree to which 
costimulation plays a deciding factor in that differentiation.    
 Cosimulatory molecules can differentially affect the outcome of T cell 
differentiation.  Not all costimulatory molecules on the surface of CD4+ naïve T cells are 
able to generate a memory phenotype. Costimulation through leukocyte function antigen-
1 (LFA-1) activates CD4+ naïve T cells to proliferate but does not protect them from 
apoptosis or generate a memory population (29, 36, 37).  ICAM-1 costimulation of CD4+ 
naïve T cells was shown by our lab to generate a memory population, however, we knew 
little about the process or timing of this differentiation.  CD28 is thought to be the 
dominant costimulatory molecule, leading to protection from apoptosis and memory cell 
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production (38).   Since CD28 is the most widely accepted costimulatory molecule for 
differentiation into memory, it is an appropriate control to compare with ICAM-1. 
 Costimulation of CD4+ naïve T cells through ICAM-1 led to an apparent delay in 
expression of differentiation molecule CD45RO compared to stimulation through CD28, 
however no delay was observed in the appearance of an effector or memory phenotype.  
In fact, memory cells were observed after only 5-7 days of costimulation through either 
ICAM-1 or CD28, during the height of the expansion in the effector population.  When 
examining the duration of signal needed for differentiation to effector and memory cells, 
we observed that naïve cells needed 5-7 days of stimulation through either CD3+ICAM-1 
or CD3+CD28 to allow detection of a differentiated population by flow cytometry at day 
12.   However,  costimulation through ICAM-1 required longer stimulation time to 
increase numbers of effector or memory cells to similar numbers observed with continual 
stimulus.  Costimulatory signal did not seem to exert a large influence on differentiation 
of naïve cells into a memory phenotype since switching costimulatory molecules at 
various time points of stimulation showed similar effects to removing the cells from 
stimulation altogether.  However, it is noteworthy that early switching of CD3+CD28 
stimulated cells to CD3 alone showed a trend of increasing the memory cell number by 
day 14.  Finally, we detected high levels of inflammatory and effector cytokines in 
supernatants at later times of cell culture indicating that the differentiation to a memory 
phenotype occured in the presence of activating molecules.   
 The debate about which path of differentiation cells take to memory is ongoing 
and there seems to be evidence to support multiple mechanisms of differentiation.  As 
mentioned earlier, there are two main proposed methods of memory generation, linear 
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and divergent, although there are also many proposed variations of each (39).  Figure 
3.23 illustrates each pathway.  Linear generation of memory hypothesizes that memory T 
cells arise from antigen induced, highly activated effector cells after the effector response 
has occurred and as the effector population undergoes contraction.  Research done by 
Joseph Opferman, et al. states that the CD8+ cells require at least 5 divisions following 
antigenic stimulation in vitro to produce a significant memory population, indicating 
linear memory development (40).  Other labs have supported the linear pathway into 
memory using antigen specific CD4+ cells and adoptive transfer.  Susan Swain generated 
antigen specific effector cells in vitro that gave rise to long-lived memory cells after 
transfer to adoptive hosts (41) and Sylvie Garcia, et al. reported that following the 
transfer of CD4+ naïve T cells into adoptive hosts, memory T cells were generated from 
activated T cells that had undergone at least 8 cell divisions (23).   The divergent pathway 
of memory T cell development suggests that memory cells appear independent of effector 
cell differentiation after initial naïve cell activation. Murine CD8+ naïve cells cultured 
with high concentrations of IL-2 during antigen activation differentiate into cells with 
effector functions (42).  However, naïve cells activated in culture with low concentrations 
of IL-2 never developed an effector phenotype but did differentiate into a memory-like 
cell, suggesting the cells took the divergent pathway to memory (42).    
  As demonstrated in the previous paragraph, much of the known research on 
memory T cell production has been done in mice and with CD8+ T cells.  The goal of the 
present research was not only to examine the role that costimulation played in the 
differentiation of CD4+ naïve T cells into a memory phenotype, but also to give more  
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Figure 3.23.  Shematic diagram of the linear and divergent pathways into memory cell 
generation during differentiation. The linear pathway generates memory cells after 
activation and differentiation into effector cells.  The divergent pathway generates 
memory cells without differentiation into effector cells.  Figure is adapted from Moulton 
and Farber, 2006 (39).
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insight into how memory cells are generated.  We have demonstrated that unlike previous 
findings (27, 28, 33, 34), CD4+ memory T cells can appear within days of primary 
stimulation, without rest or removal of inflammatory and effector cytokines.  When cells 
are removed from stimulation early, we see a decrease in the number of memory T cells 
produced but there is still a small subpopulation able to differentiate into memory.  Based 
on the late kinetic of CD45RO expression that we see with naïve T cell costimulation 
through ICAM-1, we can speculate that these cells have not undergone full activation or  
proliferation in these early time points.  At the same time, it seems that the small memory 
population that appears after CD4+ naïve T cells are removed from either ICAM-1 or 
CD28 costimulation at 1-3 days is derived from the CD11a, CD27 double negative 
quadrant of the flow dot plot, whereas the robust memory population generated from cells 
that were stimulated continuously for 7-12 days seem to be derived from the CD11a, 
CD27 double positive effector quadrant.  Together, these data may indicate that a weak or 
short stimulus could lead to memory cell, but not effector cell generation.  This 
hypothesis is supported by Yang Liu, et al. who reported that costimulation through 
CD28 and heat-stable antigen (HSA or CD24) could lead to production of effector and 
memory T cells but costimulation through CD24 alone led to only memory cell 
production since CD24 gives rise to a much weaker stimulation signal than CD28 (43).   
 A final aspect to be examined is whether the differentiation process can be 
modulated at any point following primary stimulation.  With our stimulation system we 
see that at any time point following the initial costimulatory signal being sent into the 
cell, the differentiation fate of that cell apparently is not changed with additional or 
alternate costimulatory signal.  This was demonstrated when switching the activated cells 
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to the same singular costimulatory molecule or a different costimulatory led to an effect 
similar to simply taking the cells off stimulation altogether.  One exception was that with 
cells that were stimulated through CD3+CD28 and transferred to CD3 alone at early time 
points, a slight increase memory cell number was observed.  It is conceivable that at 
those early times following stimulation, the costimulatory signal was no longer needed 
and that the continued CD3 stimulation mimicked a prolonged antigen signal, therefore 
increasing activation and differentiation through the linear pathway to memory.   
 In the perspective of previous research, the present study may support the 
hypothesis that multiple pathways exist whereby CD4+ naïve T cells differentiate into a 
memory phenotype.  In our stimulation system, continual, long term signaling appears to 
support the linear pathway where memory cell generation is derived from activated 
effector cells.  However, brief stimulation generates a small memory population without 
activation, supporting the divergent pathway of memory differentiation from precursor 
naïve T cells.  Finally, our data may also support the hypothesis that initial signal 
determines cell fate and that late, exogenous or environmental factors are not as 
influential as previously thought. Taken together, the present data may indicate that 
memory cells can develop in multiple ways depending on the stimulatory signal. 
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Chapter 4 
Homing potential of differentiated cells generated with ICAM-1 costimulation 
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Introduction 
 Chemokines are chemotactic cytokines that range from 6 to 14kDa in mass.  
There have been approximately 50 different chemokines identified (1). Chemokines can 
be classified into four groups depending on the positioning of their conserved cysteine 
residues near the N-terminus (4-6). C chemokines contain one cysteine near its N-
terminus, CC chemokines contain two, and CXC or CX3C have cysteine residues 
separated by one or three amino acids, respectively (1).  Chemokine receptors are seven 
transmembrane GTP-binding protein (G-protein) coupled receptors (GPCR)(2,3).   The 
classification of chemokine receptors is dependent on the class of chemokine that it 
binds.  There are currently 19 known chemokine receptors and the majority are classified 
as CCR or CXCR (3). Chemokines and their engagement of chemokine receptors are 
responsible for mediating cell adhesion and chemotaxic migration of leukocytes.  Once 
triggered, G proteins signal phospholipase Cβ (PLCβ) isoforms, phosphatidylinositol 3-
kinase-γ (PI3Kγ), Serine /Threonine-kinases and c-Src-related non-receptor tyrosine 
kinases (4,7,8).  
 Chemokines, and thus chemokine receptors, are also grouped by function.  
Homeostatic chemokines are constitutively expressed in particular microenvironments 
and responsible for maintaining circulation of leukocytes (specifically lymphocytes) 
between periphery and secondary lymphoid organs in order to look for cognate antigen 
(9-12).  This chemokine function is essential for immune surveillance by naïve and 
memory T cells which can lead to their specific activation and ability to travel to a 
secondary site of immune response.  Another function of chemokines is referred to as 
inflammatory or inducible.  This function occurs following leukocyte activation or 
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stimulation by pro-inflammatory cytokines and directs cells to inflamed tissue where 
their effector function can be brought into play (9-12).  Chemokines can also induce 
activation of integrins present on leukocyte cell surface; this is an essential step in 
initiating the cell migration process. This process begins with leukocyte tumbling over 
the endothelial cell surface as a part of blood flow and low affinity interactions between 
selectins on leukocytes and endothelial cells lining the vessel.  Tumbling, or rolling, 
allows leukocyte exposure endothelial cell surface chemokines (13).  Binding to the 
chemokine receptor leads to high affinity integrin interactions with adhesion molecules 
on the surface of the endothelial cells and arrests the leukocyte tumbling.  Finally, 
leukocytes are able to extravasate through vascular endothelial junctions into surrounding 
tissue.  A similar process is used for lymphocytes migrating through high endothelial 
venule (HEV) cells into secondary lymphoid organs.   
 Differential chemokine receptor expression on T cells is indicative of which 
chemokines that particular cell can respond to and, in turn, where that cell can go in the 
body.  Also, subsets of T cells at various stages of activation or differentiation will 
express particular chemokine receptors that can direct those cells to specific locations in 
the body.    In this chapter we will examine the phenotype of CD4+ naïve T cells before 
and following differentiation induced by different costimulatory molecules and whether 
that phenotype can be modulated with the addition of external factors.  Our hypothesis is 
that T cell activation through specific costimulatory molecules can differentially affect 
the homing patterns of the differentiated cell.   
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Materials	  and	  Methods	  
	  
Antibodies and Reagents 
Anti-CD54 (R6.5D6) was purchased from BioXCell (West Lebanon, NH),  anti-CD28 
(clone ANC28.1) was purchased from Ancell (Minneapolis, MN) and anti-CD3 (OKT3) 
was purchased from eBioscience (San Diego, CA).  Anti-CCR7-PE, anti-CCR5-PE, anti-
CXCR5-PE and anti-CCR9-PE were purchased from R&D Systems (Minneapolis, MN).  
Anti-CD62L-TriColor, anti-CXCR4-PE, anti-CD45RO-FITC/APC and flagellin from S. 
typhimurium were purchased from Caltag Laboratories of Invitrogen (Burlingame, CA).  
Anti-CD127-PE, and anti-β7-PECy5 were purchased from Becton Dickinson (San Jose 
CA).  anti-CD45RO-FITC Caltag (Burlingame, CA). Anti α4-PE was purchased from 
eBioscience (San Diego, CA) and retinoic acid was purchased from Sigma-Aldrich (St. 
Louis, MO).  
 
Cell Purification 
Naïve human CD4+ T cells were isolated from peripheral blood or tonsil of multiple 
donors by negative selection using a naïve T cell enrichment kit (Stem Cell Technologies, 
Vancouver, BC, Canada).  All magnetically selected naïve CD4+ T cell populations were 
of >98% purity as assessed by flow cytometry.  In the present work, purified naïve 
human T cells represents cells that are CD4(+) CD45RA(+)RO(-) CD11alo CD27(+).   
 
T cell Stimulation 
Antibodies in PBS were attached to tissue culture-treated plates (Midwest Scientific, St. 
Louis, MO) by incubation at 37°C for 2 hours or overnight at 4°C, and wells were 
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washed three times with PBS to remove unbound antibody.  Naïve CD4+ T cells were 
added at a concentration between 1-2×106 / ml, and stimulated with 1 µg/ml anti-CD3 
plus 10 µg/ml anti-ICAM-1, or 2 µg / ml anti-CD28.  Retinoic acid or bacterial flagellin 
protein was added at the start of cell culture and used at a concentration of 1 nM or 5 nM 
for retinoic acid and 1 nM for flagellin.  Optimal antibody concentrations were 
determined based on the minimum dose that led to maximum T cell proliferation (not 
shown).  
 
Flow Cytometry 
Flow cytometry was performed using the FACScan (Becton Dickinson, San Jose CA) 
and the Accuri C6 Flow Cytometer System (Accuri Cytomoters, Ann Arbor MI).  The 
FACScan was calibrated using CaliBRITE beads (Becton Dickinson), and the Accuri C6 
was calibrated using Sphero APC Calibration Particles (Spherotech, Inc. Lake Forest, 
IL).  This was supplemented by compensation using singly stained cells.  Data were 
analyzed using Cell Quest (Becton Dickenson), FlowJo (Tree Star Inc, Ashland, OR) and 
CFlow (Accuri Cytometers). 
 
Statistical analysis. 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA.) or SigmaStat (Systat Software Inc. San Jose, CA).  Statistical tests and significance 
for individual figures are indicated in figure legends. 
	   131	  
Results 
CCR7 expression is maintained following activation of CD4+ naïve T cells costimulated 
through ICAM-1 or CD28 
 
 CCR7 is the classic chemokine receptor that directs naïve and memory T cells to 
the lymph nodes where they can encounter cognate antigen to undergo activation (14,15).  
The process of naïve and memory T cell recirculation between the periphery and lymph 
nodes is essential to initiate immune responses.  The chemokines that bind to CCR7 are 
CCL21 and CCL19 and are expressed on HEVs in the venule lumen (16-19).  Mice that 
lack either expression of CCR7 or its chemokines have been found to be defective in 
chemokine regulated homing illustrating their importance in lymphocyte migration and 
entry into the lymph node (20-22).  As expected, almost all of CD4+ naïve T cells 
express CCR7 (Fig. 4.1, 4.2).  Following stimulation through CD3+ICAM-1 
effector/memory cells (cells that express CD45RO) exhibited a decrease of CCR7 (Fig. 
4.1, 4.2).  This would be expected knowing that activated/effector cells do not completely 
retain ability to home to the lymph node (23).  The subset of memory T cells known as 
“central memory” or TCM has been characterized to be CCR7 and CD62L positive (24).  
After costimulation of CD4+ naïve T cells through ICAM-1, the percent of CD45RO+ 
cells that expressed CCR7 was slightly higher than cells costimulated through CD28 
(60% versus 50% CCR7 positive, respectively) (Fig. 4.1, 4.2).   
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Figure 4.1 
Figure 4.2 
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Figure 4.1, 4.2.  CCR7 expression is maintained following activation of CD4+ naïve T 
cells costimulated through ICAM-1 or CD28.  Percent CCR7 positive of isolated CD4+ 
naïve T cells was determined by flow cytometry.  Naïve cells were stimulated through 
CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were gated on CD45RO and CCR7 
positive cells were determined by flow cytometry.  Representative flow plots (4.1) and 
cumulative data (4.2) are shown. Data are presented as mean ± SEM, **p<0.01, 
***p<0.001 using two tailed t-Test.  n=9, naïve cells; n=5, CD3+CD54; n=6, 
CD3+CD28.  
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Costimulation of CD4+ naïve T cells through ICAM-1 results in a decreased CD62L 
expression compared to costimulation through CD28.  
 L-selectin (CD62L) is present on the surface of many leukocyte subsets including 
naïve T cells and some effector and memory T cells.  They bind to peripheral-node 
GlyCAM-1 on HEVs to facilitate entry into lymph nodes (25).  Studies have shown that 
impairment CD62L expression in mice will lead to a massive depletion of T cells in the 
peripheral lymph nodes (26).  L-selectin can also mediate homing to the gut by binding 
mucosal vascular cell-adhesion molecule-1 (MAdCAM-1) on the HEVs of the gut-
associated lymphoid tissue (GALT) (27). After activation, Effector T cells and effector 
memory T cells (TEM) decrease the L-selectin on their cell surface in order to allow 
activated T cells to migrate to sights of inflammation, and to the gut (via integrin α4β7) 
and skin to carry out effector functions where needed (25,28).  Much like CCR7, the 
CD4+ naïve T cells that we isolated were positive for CD62L (Fig. 4.3, 4.4).  As 
expected, after costimulation the activated/differentiated cells did downregulate CD62L 
expression, however, the CD4+ naïve T cells stimulated with CD3+ICAM-1 decreased 
surface expression (about 45% CD62L positive) more so than the cells stimulated 
through CD3+CD28 (about 55% CD62L positive) but the difference was not significant 
(Fig. 4.3, 4.4).  
IL-7 receptor α subunit is expressed at low levels on mature T cells following 
costimulation through either ICAM-1 or CD28 
 The IL-7 receptor α subunit (CD127) is not involved in directing T cell homing, 
however like CCR7 and CD62L, CD127 can be used as a marker for naïve and central 
memory T cell subsets.  CD127 is present on the surface of naïve T cells and its  
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Figure 4.3 
Figure 4.4 
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Figure 4.3, 4.4. Costimulation of CD4+ naïve T cells through ICAM-1 results in a 
decreased CD62L expression compared to costimulation through CD28. Percent CD62L 
positive of isolated CD4+ naïve T cells was determined by flow cytometry.   Naïve cells 
were stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were gated on 
CD45RO and CD62L postitve cells were determined by flow cytometry. Representative 
flow plots (4.3) and cumulative data (4.4) are shown.  Data are presented as mean ± 
SEM, **p<0.01 using two tailed t-Test.  n=6, naïve cells; n=4, CD3+CD54; n=5, 
CD3+CD28.  
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expression is downregulated soon after activation of the cell (29,30).  T cells that 
maintain or upregulate CD127 following activation can transition to a memory cell 
phenotype (31-35).  CD127 is expressed on naïve and memory T cells because it is 
necessary for long-term cell survival by increasing expression of anti-apoptotic proteins, 
Bcl-2 and Glut1 (36-38).  As with CCR7 and CD62L, CD127 was expressed on our 
isolated CD4+ naïve cells (Fig. 4.5, 4.6).   Following costimulation of the naïve cells 
through ICAM-1 or CD28, the expression of CD127 was dramatically reduced on 
CD45RO+ T cells, however, a small population remained CD127 positive for both sets of 
costimualtion (20% CD127 positive with ICAM-1 and 30% positive for CD28) (Fig. 4.5, 
4.6).  Since CD127 is not expressed on effector cells, it seems logical that the cells 
retaining expression of CD127 after 14 days of stimulation would correlate to a central 
memory T cell population because CD45RA positive naïve cells were gated out of the 
analyzed population.  
 
Inflammatory chemokine receptor expression does not significantly change following T 
cell activation through ICAM-1 or CD28 
 CCR5 is known to be an inflammatory chemokine receptor and is not expressed 
on the surface of resting T cells (39).  Expression of inflammatory chemokine receptors 
allows effector T cells to directly enter sites of inflammation.  CCR5 can  
respond to multiple chemokines including RANTES, MIP-1α, MIP-1β and MCP-2 (12).  
Upon naïve or resting T cell activation, CCR5 can be upregulated preferentially on Th1 
cells and generally 5-15 percent of peripheral blood T cells are CCR5 positive (40,41). 
Expression of CCR5 has also been associated with autoimmune diseases that are largely  
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Figure 4.6 
Figure 4.5 
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Figure 4.5, 4.6. IL-7 receptor is expressed at low levels on mature T cells following 
costimulation through either ICAM-1 or CD28. Percent CD127 (IL-7Rα) positive of 
isolated CD4+ naïve T cells was determined by flow cytometry.  Naïve cells were 
stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were gated on 
CD45RO and CD127 positive cells were determined by flow cytometry. Representative 
flow plots (4.5) and cumulative data (4.6) are shown.  Data are presented as mean ± 
SEM, ***p<0.001 using two tailed t-Test.  n=3, naïve cells; n=3, CD3+CD54; n=3, 
CD3+CD28.  
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Th1 driven since nearly all of the auto-reactive T cells are found to be CCR5 positive 
(42,43).  CCR5 was expressed at very low levels (under 5%) on our isolated CD4+ naïve 
T cells (Fig. 4.7, 4.8).  Costimulation through ICAM-1 or CD28 slightly increased CCR5 
expression to 12% positive for ICAM-1 and 9% positive for CD28 (Fig. 4.7, 4.8).  The 
increase in CCR5 expression with cells costimulated through ICAM-1 as opposed to 
CD28 is justified since costimulation through ICAM-1 gives a mainly Th1 population 
and costimulation through CD28 leads to both Th1 and Th2 populations (44).  These data 
conflict with previous findings from Dr. Jake Kohlmeier (unpublished data) taken at 5 
and 10 days after stimulation looking at total T cells.  However, different time points of 
analysis, thus, different T cell populations examined shows that CCR5 expression 
changes with differentiation.  The present data fall in line nicely with the known percent 
expression of CCR5 by resting peripheral T cells and could be expected from cells 
analyzed 14 days after stimulation when the effector phenotype would be contracting.  It 
is of considerable interest to use this system to identify what determines which of the 
naïve T cell population responds to signals by turning on CCR5, and why. 
 
Preliminary data: CXCR4 expression mimics CCR7 expression in CD4+ naïve T cells 
and following costimulation through ICAM-1 or CD28 
 CXCR4 is broadly expressed on many leukocytes and during all T cell 
developmental stages.  The ligand for CXCR4 is stromal cell-derived factor- 1 (SDF-1) 
or CXCL12.   SDF-1 is widely expressed throughout the body in primary and secondary 
lymphoid tissue and peripheral tissues (12).  The ubiquitous expression of SDF-1 and 
CXCR4 suggests multiple roles in leukocyte homing, function and homeostasis (45-48).   
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Figure 4.7 
Figure 4.8 
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Figure 4.7, 4.8. Inflammatory chemokine receptor expression does not significantly 
change following T cell activation through ICAM-1 or CD28.  Percent CCR5 positive of 
isolated CD4+ naïve T cells was determined by flow cytometry.  Naïve cells were 
stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were gated on 
CD45RO and CCR5 postitve cells were determined by flow cytometry. Representative 
flow plots (4.7) and cumulative data (4.8) are shown.Data are presented as mean ± SEM 
and significance was determined using a two tailed t-Test.  n=5, naïve cells; n=5, 
CD3+CD54; n=6, CD3+CD28.  
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 Studies have shown that CXCR4 also contributes to central memory T cell entry 
into the peripheral lymph nodes (PLN) (49).  Our isolated CD4+ naïve T cells exhibited 
nearly 100 percent expression of CXCR4.  After costimulation of naïve cells, the 
resulting activated/memory cells costimulated through ICAM-1 showed about 60 percent 
and cells costimulated through CD28 retained 50 percent (Fig. 4.9, 4.10).  Figure 5 
illustrates a pattern of CXCR4 expression that is similar to expression of CCR7 on naïve 
CD4+ T cells and on cells stimulated through ICAM-1 or CD28 suggesting that in our 
stimulation system, CXCR4 could assist CCR7 in T cell migration to the PLNs.  
 
Preliminary data: CXCR5 may define a small subset of memory T cells generated by 
costimulation through ICAM-1 or CD28 
 CXCR5 binds BCA-1 (B cell–activating chemokine 1) in secondary lymphoid 
tissue; is not expressed on CD4+ naïve T cells but is present on a subset called follicular 
helper T cells (TFH) that help form follicles in secondary lymphoid tissue (50,51).  
CXCR5 expression is unique in that it is rapidly induced (2-3 days after stimulation) 
before T cell differentiation, and subsequently lost during proliferation (52).  Long term 
CXCR5 expression can characterize a subset of memory T cells, the vast majority being 
CD4+, where peripheral CXCR5+ T cells coexpress CCR7 and tonsillar CXCR5+ T cells 
do not (53).  Therefore expression of CXCR5 represents a subpopulation of central 
memory T cells with B cell helper function (53).  CXCR5 was not expressed on our 
isolated CD4+ naïve T cells, as expected, and only slightly expressed on cells stimulated 
for 14 days through CD3+ICAM-1 or CD3+CD28 only at about 4% and 5% positive, 
respectively (Fig. 4.11,12).   Since CXCR5 is rapidly lost from activated/dividing cells, it  
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Figure 4.9 
Figure 4.10 
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Figure 4.9, 4.10. Preliminary data: CXCR4 expression mimics CCR7 expression in CD4+ 
naïve T cells and following costimulation through ICAM-1 or CD28.  Percent of isolated 
CD4+ naïve T cells that were positive for CXCR4 was determined by flow cytometry.  
Naïve cells were stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells 
were gated on CD45RO and CXCR4 postitve cells were determined by flow cytometry. 
Representative flow plots (4.9) and cumulative data (4.10) are shown. Data are presented 
as mean ± SEM, **p<0.01 using two tailed t-Test.  n=2, naïve cells; n=1, CD3+CD54; 
n=2, CD3+CD28.   
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Figure 4.11 
Figure 4.12 
Day 0 CD3+ICAM-1 CD3+CD28 
CXCR5 
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Figure 4.11, 4.12. Preliminary data: CXCR5 may define a small subset of memory T cells 
generated by costimulation through ICAM-1 or CD28.  Percent of isolated CD4+ naïve T 
cells positive for CXCR5 was determined by flow cytometry.  Naïve cells were 
stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were gated on 
CD45RO and CXCR5 postitve cells were determined by flow cytometry. Representative 
flow plots (4.11) and cumulative data (4.12) are shown. Data are presented as mean ± 
SEM and significance was determined using a two tailed t-Test.  n=3, naïve cells; n=1, 
CD3+CD54; n=2, CD3+CD28.  
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seems possible that CXCR5 may define a small subset of central memory T cells in 
response to costimulation through ICAM-1 or CD28 in vitro.  It is interesting that the 
baseline percentage did not really vary over the 14 days.  This seems to suggest some sort 
of homeostatic necessity for a low percentage of these cells. 
 
Costimulation of naïve CD4+ T cells through ICAM-1 or CD28 drastically increases 
expression of gut homing integrin α4β7 when the cells are co-cultured with retinoic acid 
 Migration to lymphoid tissue in the gut, particularly under non-inflamed 
conditions, is mediated in part by the integrin α4β7 on the surface of T cells (54). α4β7 
binds to its ligand MAdCAM-1 expressed in gut lamina propria venules (55,56).  α4β7 
expression on our freshly isolated CD4+ naïve T cells was just over 50% (Fig. 4.13, 
4.14).  The integrin expression seems slightly elevated considering that naïve cells are 
thought to express low levels of α4β7.  However, naïve T cells use α4β7-MAdCAM-1 
interactions to enter the Peyer’s patches and mesenteric lymph nodes as they circulate 
throughout the body (58), possibly explaining our observations.  By day 14 the 
CD45RO+ cells that had been stimulated through either CD3+ICAM-1 or CD3+CD28 
displayed a decrease in α4β7 expression and therefore gut homing potential (Fig. 4.13, 
4.14).  Due to the expression of possible lymph node homing molecules, CCR7, CD62L 
and CXCR4, on the differentiated cells at day 14 it seems likely that a larger subset of 
these cells would preferentially home to the peripheral lymph nodes (PLNs) as opposed 
to secondary lymphoid tissue in the gut.   
 Retinoic acid is a metabolite of vitamin A.  The role of retinoic acid in gut 
homing by T cells was characterized by others using vitamin A deficient mice that lacked  
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Figure 4.13 
Figure 4.14 
Figure 4.15 
	   150	  
Figure 4.13-4.15. Costimulation of naïve CD4+ T cells through ICAM-1 or CD28 
drastically increased expression of gut homing integrin α4β7 when co-cultured with 
retinoic acid.  A) Percent of isolated CD4+ naïve T cells positive for α4β7 was 
determined by flow cytometry.  Naïve cells were stimulated through CD3+ICAM-1 or 
CD3+CD28 for 14 days. Cells were cultured with stimulus alone, 1-5 nM retinoic acid or 
1 nM flagellin.  Cells were gated on CD45RO and α4β7 postitve cells were determined 
by flow cytometry. Representative flow plots (4.13) and cumulative data (4.14) are 
shown.  Figure 4.15) Naïve cells were stimulated through CD3+ICAM-1 or CD3+ICAM-
1+ retinoic acid for 14 days; CD62L expression was measured by flow cytometry. Data 
are presented as mean ± SEM, *p<0.05, ***p<0.001 using two tailed t-Test.  n=5, naïve 
cells; n=5, CD3+CD54; n=3, CD3+CD28; n=4, CD3+CD54+RA; n=2, CD3+CD28+RA; 
n=4, CD3+CD54+flagellin; n=2, CD3+CD28+flagellin.    
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effector and memory T cells in the gut mucosa while T cells in other lymphoid tissue 
remained unaltered (57).  The biosynthesis of retinoic acid from vitamin A is an 
enzymatic process performed by retinaldehyde dehydrogenases (RALDHs).  Vitamin A  
is produced by dendritic cells in Peyer’s patches and draining mesenteric lymph nodes 
but not spleen or peripheral lymph nodes (57).  Retinoic acid is essential for inducing gut 
homing properties in T cells.   We wanted to determine if we could modulate gut homing 
properties of cells using our stimulation system in conjunction with retinoic acid.  After 
14 days of costimulation through ICAM-1 or CD28 in the presence of exogenous retinoic 
acid, the expression of α4β7 sharply increased compared to costimulation alone (Fig. 
4.14, 4.15).   Nearly all of the cells were positive for α4β7 and this observation is 
supported by the simultaneous decrease in the PLN homing molecule, CD62L, following 
stimulation through CD3+ICAM-1 with retinoic acid as opposed to stimulation without 
retinoic acid (Fig. 4.15).   
 Bacterial flagellin protein and its receptor, toll like receptor 5 (TLR5), have been 
implicated as an inducing factor of the inflammatory bowel disease, Crohn’s disease 
(CD) (59,60).  Inflammatory bowel disease (IBD) is characterized by infiltrating 
colitogenic effector/memory CD4+ T cells into the mucosa and subsequently induced gut 
wall damage by inflammation (61).  Activation of the TLR pathway, directed by MyD88, 
has been directly implicated in the maintenance of IBD through expansion of colitogenic 
CD4+ T cells (62).  To address the question whether flagellin protein also plays a role in 
modulating migration of our effector/memory T cells, CD4+ naïve T cells were 
costimulated through ICAM-1 or CD28 in the presence of flagellin, and α4β7 expression 
was measured after 14 days.  The cells cultured with flagellin did not increase their α4β7 
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expression compared to cells stimulated without flagellin.  This indicates that triggering 
TLR5 on the surface of activated T cells did not play a role in modulating homing 
patterns of the cells in our stimulation system (Fig. 4.14). 
 
Expression of small intestine homing chemokine receptor CCR9 was not induced by 
costimulation of naïve CD4+ T cells through ICAM-1 or CD28 regardless of the addition 
of retinoic acid or bacterial flagellin protein 
 CCR9 is a chemokine receptor that is important in homing of effector T cells to 
the gut (63).  The ligand for CCR9, CCL25, is expressed on endothelial cells in the small 
intestine and on lamina propria cells but not in epithelium from the colon (63,64).  Most 
human naïve T cells in adults lack expression of CCR9 because it is thought that CCR9 is 
more important for antigen-induced migration to the gut rather than peripheral circulation 
(65).  Approximately 28% of our freshly isolated CD4+ naïve T cells express CCR9.  
This level of naïve T cell expression is not unreasonable since it has been suggested that 
recent thymic emigrants express CCR9 (66).  Following costimulation of our CD4+ naïve 
T cells through ICAM-1 for 14 days, the percentage of CCR9 positive cells did not 
change suggesting that the circulating memory population retains the ability to enter the 
gut similar to naïve (Fig. 4.16, 4.17).  Retinoic acid has been shown to enhance CCR9 
mRNA levels and increase migration in response to CCL25 in vitro when CD4+ T cells 
were stimulated through CD3+CD28 with retinoic acid for 2-4 days (57).  With our 
stimulation system in the presence of retinoic acid, the percentage of differentiated cells 
costimulated through ICAM-1 that expressed CCR9 dropped about 20% down to about  
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Figure 4.16, 4.17. Expression of small intestine homing chemokine receptor CCR9 is not 
induced by costimulation of naïve CD4+ T cells through ICAM-1 or CD28 regardless of 
the addition of retinoic acid or bacterial flagellin protein.  Percent of isolated CD4+ naïve 
T cells that were positive for CCR9 was determined by flow cytometry.  Naïve cells were 
stimulated through CD3+ICAM-1 or CD3+CD28 for 14 days. Cells were cultured with 
stimulus alone, 1-5 nM retinoic acid or 1 nM flagellin.  Cells were gated on CD45RO and 
CCR9 positive cells were determined by flow cytometry. Representative flow plots (4.16) 
and cumulative data (4.17) are shown.  Data are presented as mean ± SEM and 
significance was determined using two tailed t-Test.  n=3, naïve cells; n=3, CD3+CD54; 
n=1, CD3+CD28; n=3, CD3+CD54+RA; n=1, CD3+CD28+RA; n=3, 
CD3+CD54+flagellin; n=1, CD3+CD28+flagellin.
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10 % compared with stimulation without retinoic acid (Fig. 4.16, 4.17).  Therefore, 
stimulation of our CD4+ naïve T cells for 14 days with retinoic acid instead of total 
CD4+ T cells stimulated for 2-4 days with the addition of retinoic acid indicates that the 
increase observed in CCR9 expression by other labs may be an activation induced 
expression from primed cells that does not continue with an effector memory or central 
memory population differentiated from naïve cells.  We also wanted to determine if 
triggering TLR5 with flagellin protein had an affect on CCR9 expression as we did in the 
Figure 7A where we measured α4β7.  The addition of bacterial flagellin protein to CD4+ 
naïve T cells stimulated through CD3+ICAM-1 for 14 days induced minimal change in 
the percent of CCR9 positive cells, only decreasing the percent positive about 8% from 
cells stimulated without flagellin (Fig. 4.16, 4.17).  Preliminary data of CCR9 expression 
with cells costimulated through CD28 indicates that the percent of differentiated cells that 
express CCR9 is low (about 10%) following 14 days of stimulation through CD3+CD28 
alone (Fig. 8).  The addition of either retinoic acid or flagellin to costimulation through 
CD28 did not have much impact on the percent of CCR9 positive cells, dropping it to 
about 5% (Fig. 4.17).  This suggests that costimulation of CD4+ naïve T cells through 
CD28 does not maintain a significant CCR9 expressing population and, as with cells 
costimulated through ICAM-1, the addition of retinoic acid or flagellin did not induce a 
CCR9 dependent gut homing population.  Although CCR9 is thought to be an important 
component for T cell homing to the gut (especially the small intestine) supported by the 
fact that blocking CCL25 or a deficiency in CCR9 leads to reduced antigen specific 
CD8+ T cells in the small intestine (67, 68), more recent evidence suggests that a large 
subset of CD4+ effector T cells home to the small intestine in a CCR9 independent 
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manner (69).  Therefore, the ability to modulate CCR9 expression may not be as 
important that the ability to modulate α4β7 expression when the desired outcome is to 
develop an effector memory or central memory T cell that has gut homing capabilities. 
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Discussion 
 Expression of chemokine receptors and other developmental or homing receptors 
on the surface of T cells provide homing guidance during migration and in this context, 
indicate differentiated subpopulations following activation.  In the present study we 
initiated a characterization of some of these cell surface receptors as they occur when 
human CD4+ naïve T cells differentiate in our in vitro system.  The goal was to identify 
changes in homing characteristics following stimulation, what phenotype the 
differentiated cells displayed and whether these parameters differed between 
costimulation through ICAM-1 and CD28. Overall, our data suggests that we are of 
creating a PLN homing memory population when we costimulate CD4+ naïve T cells 
through ICAM-1.  We found no significant differences between costimulation through 
ICAM-1 or CD28 in the expression of many of the surface homing molecules studied.  
Slight difference in surface molecule expression were seen but were never greater than a 
ten percent differential.  Costimulation of CD4+ naïve T cells through ICAM-1 or CD28 
for 14 days led to mature CD45RO+ cells that expressed many memory-like phenotype 
receptors such as CCR7, CD62L, CXCR4 and to a lesser extent CD127 and CXCR5.  
The homing receptors CCR7 and CD62L direct T cells to the lymph node and help to 
define a central memory cell population (24) along with CD127, which is necessary for 
long-term memory cell survival (36-38).  CXCR5 is often co-expressed with CCR7 in the 
periphery to define a subset of memory cells that are required for rapid antibody response 
by follicular B cells (53, 70) and CXCR4 has multiple roles in homing and function but 
its expression similarity to CCR7 may suggest facilitation of homing to the PLNs (49).   
A small percentage of the CD45RO+ cells also expressed CCR5, which is an 
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inflammatory homing molecule (39).  CCR5 is only expressed on activated cells and 
given the low percentage of CCR5 expressing cells that we observed, it can be speculated 
that these cells are part of a late activating subset that remain in the culture as the effector 
cells undergo contraction.  Another factor that may support our hypothesis that we are of 
creating a PLN homing memory population is that after costimulation through ICAM-1 
or CD28 for 14 days, gut homing receptors α4β7 and CCR9 generally diminished in 
expression (with the exception of CCR9 after ICAM-1 costimulation).  This indicates to 
us that the differentiated population generated after costimulation through ICAM-1 or 
CD28 largely homes to secondary lymphoid organs, specifically PLNs, and not to 
effector sites.  Also, these homing patterns can be modulated as shown with the increase 
in α4β7 and decrease of CD62L upon addition of retinoic acid in culture.  This suggests a 
plasticity reminiscent of that observed using in vivo studies and supports our assertion 
that our in vitro model replicates the in vivo situation in many ways.   
 The role that CD28 costimulation plays in cell migration has been studied in 
considerable detail.  CD28 assists in the ability of primed T cells to leave lymphoid tissue 
and migrate to sites of inflammation (25, 71). Also, stimulation of total T cells through 
CD3+CD28 increases early CCR7 dependent migration to PLN followed by a decrease in 
LN homing potential a few days later (72).  However, many of these studies examine 
chemokine receptor modulation after a few days of activation, not through long-term 
development to memory phenotype or with a starting naïve T cell population.  In 
addition, the impact of costimulation of naïve T cells through ICAM-1 on chemokine 
receptor expression is largely unknown.  
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 Figure 4.18 diagrams what is known about where differentiated subsets of T cells 
can home.  It is known that CD4+ naïve T cells use CCR7, CD62L and possibly CXCR4 
to enter the peripheral lymph nodes through high endothelial venules (HEVs) (16-19,25).  
Naïve cells also can circulate through the mesenteric lymph nodes and peyer’s patches 
using the integrin α4β7 (58).  Upon activation, effector and effector memory T cells 
change their homing potential allow them to target sites where they are no longer just 
monitoring microenvironments but can carry out necessary immunological functions.  
CCR5 can facilitate cell migration to sites of inflammation (39) while CCR9 and α4β7 
help in cellular homing to the gut laminia propria (55, 56, 63).  Central memory T cells 
display a lymph node homing, nonpolarized phenotype, much like naïve cells. Some 
central memory cells can also circulate to the gut via α4β7 (25) and through the 
periphery and bone marrow based on using CXCR4 and the widespread expression of its 
ligand, SDF-1 (73). Figure 4.19 illustrates that costimulation of naïve T cells through 
ICAM-1 generates CD45RO+ cells that resemble the population with central memory-
like homing capabilities from Figure 4.18 after 14 days of stimulation.  Additionally, 
following the same culturing protocol with costimulation through CD28 yields similar 
results to ICAM-1.   
 Our results also support the premise that, under the right conditions, the homing 
outcome of stimulated cells can be changed.  We observed this by using the addition of 
retinoic acid to cause an increase of α4β7 expression.  The ability to harness and/or 
modulate T cells’ homing potential could have important implications in the development 
of T cell therapies or in treating autoimmune diseases.  For example, during acute HIV-1 
infection CD4+ T cells are rapidly depleted from the gut and remain depleted even after  
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Figure 4.19 
Figure 4.18 
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Figure 4.18) Diagram of known chemokine receptor and cell surface markers at naïve, 
central memory (TCM), effector (TEFF), and effector memory (TEM) developmental stages 
of activation. Figure 4.19) Semi-quantification of surface molecule expression in our 
study after CD4+ naïve T cells were stimulated through CD3+ICAM-1 for 14 days.  
(+++) indicates high expression, (++) indicates medium expression and (+) indicates low 
expression. LN= lymph node, PP= peyer’s patch.  Figure adapted from FM Marelli-Berg, 
et al. (25).  
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antiviral therapy due to defective recruitment (74).  The ability to upregulate the 
expression of α4β7 on T cells to induce gut migration could provide help in 
reconstituting the immune system in immunodeficient patients since the gut is an 
essential component in maintaining immunological competence.  Similarly, induction of 
gut homing T cells could have a vast impact on controlling diarrheal diseases, which can 
be devastating and frequently fatal for children in developing countries.  
Hammerschmidt, et al. demonstrated some success in increasing the presence of gut 
homing T cells using subcutaneous injections of retinoic acid in mice, this treatment 
increased α4β7 expression on T cells by 30-40 percent in skin-draining lymph nodes 
(75).  We observed a dramatic increase of α4β7 when we added retinoic acid to our 
cultures.  The concept of specifically increasing the numbers of antigen specific T cells 
that home to the gut using costimulation through ICAM-1 along with retinoic acid could 
be a powerful and efficient tool to induce a specific immune response in the intestine.   
 Chemokines and their receptors are also involved in the development of cancers 
and are currently being investigated as targets of therapies.  SDF-1 and CXCR4 have 
been shown to have roles in the development and progression of breast, prostate, colon, 
ovarian and other tumor types (76-79).  In ovarian cancer, SDF-1 produced in the tumor 
microenvironment and CXCR7 (a second SDF-1 receptor) expressed on tumor cells are 
responsible for proliferation and survival of tumor cells (80).  SDF-1 also is responsible 
for recruitment of immunosuppressive cells into the tumor to combat the anti-tumor 
effects of leukocytes (81).  It is conceivable that using our stimulation system, which 
leads to a high percentage of CXCR4 T cells when costimulated through ICAM-1, we 
could generate tumor specific T cells in vitro.   The tumor specific T cells would be used 
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for their homing capabilities to lymph nodes and tumor microenvironments to sustain 
long term anti-tumor activity.   
 In summary, we have identified a pattern of expression of chemokine receptors 
and other cell surface molecules on the T cells that we generated using ICAM-1 
costimulation.  This pattern apperars to define effector memory and central memory 
populations based on the homing capabilities provided by the various cell surface 
proteins.  In addition, we have demonstrated an ability to modulate homing potential of 
these cells to the gut as measured increased expression of α4β7 with the addition of 
retinoic acid to ICAM-1 or CD28 stimulation.  The work presented here may also have 
important implications in the development of possible immunotherapies for infections 
and cancers. 
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Chapter 5 
 
Costimulation of CD4+ naïve T cells through ICAM-1 generates a memory 
phenotype in older individuals 
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Introduction  
With age, the immune response can lose ability to respond to disease causing 
organisms and to be properly regulated.  Older humans produce and harbor fewer thymic 
derived naive T cells and this has been proposed as one of the factors involved in 
declining function of the immune system also known as immunosenescence (1).  The 
capability of naive CD4+ human T cells from older individuals to activate and respond to 
a specific foreign disease causing organism (immunogen) is not fully characterized and 
description of this capability should lead to conclusions about immunosenescence. 
As mentioned earlier, naïve T cells require two signals in order to become fully 
activated.  The first is through the T cell receptor (TCR)/CD3 complex.  The second 
signal is delivered through the costimulatory molecule and is independent of antigen 
specificity (2).   After antigen encounter, naïve T cells undergo differentiation and clonal 
expansion into an effector cell population which eventually contracts leaving memory 
cells (3,4).  Without the presence of this second signal the cell can become anergic or 
apoptotic (5,6).  Memory T cells are longer lived in the body than effector cells, activate 
quicker and require less costimulation than naïve T cells (7-9).   
 In young, healthy individuals, naïve T cells are capable of being activated by 
multiple different costimulatory molecules.  CD28 is a well-characterized costimulatory 
molecule.  Costimulation through CD28 by its ligands B7-1 and B7-2 on an APC can 
induce cell proliferation and IL-2 secretion, generate Th1 and Th2 subsets, protect the 
cell from apoptosis and lead to an increase in memory T cells (10-12).  Leukocyte 
Function-associated Antigen-1 (LFA-1) on the T cell surface also can serve a 
costimulatory role when interacting with ICAM-1 on APCs.  Costimulation through 
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LFA-1 can initiate cell activation and proliferation but does not drive cells to memory 
and many of the cells die by apoptosis (13-15).  Intercellular Adhesion Molecule-1 
(ICAM-1) resident on T cells also functions as a classic second signal.  Costimulation of 
human naïve CD4+ T cells from younger subjects through ICAM-1 induces 
differentiation to memory T cells, making ICAM-1 the only molecule identified thus far 
besides CD28 that is expressed on human naïve T cells and capable of costimulation 
leading to generation of memory cells (15).  It has also been observed that costimulation 
through ICAM-1 can differentiate naïve CD4+ T cells into suppressive regulatory T cells 
(16).   
 Age associated changes in T cells are in part responsible for a decline in the 
immune response in the elderly.  Older individuals display both a reduced diversity of T 
cells as well as an accumulation in T cells that are defective in activation and function.  
The defect in T cell proliferation, differentiation and survival can be partially attributed to 
an increase in T cells that lack CD28 expression (17-20).  This CD28(-) T cell population 
is not seen in mice.  However, murine CD4+ cells from older mice showed a decrease in 
IL-2 production after stimulation with anti-CD3 and anti-CD28 mAb when compared to 
younger mice illustrating a decrease in T cell CD28 response with age despite CD28 
expression (21).  There is also evidence that in older mice, Tregs expressing an 
effector/memory phenotype can induce a downregulation in expression of the CD28 
counter-receptor, CD86, in dendritic cells leading to an impaired T cell response (22).    
 The accumulation of defects in CD4+ T cells, in addition to costimulation defects, 
lead to the weakened immune function observed older individuals.  A reduction in TCR 
signaling can be attributed to inefficient immunological synapse formation and reduction 
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in intracellular signaling complex formation (23-25).  Impaired TCR signaling likely has 
a role in diminished T cell expansion and IL-2 secretion observed in aging mouse models 
(26) DNA damage from chronic infection or defects in DNA damage repair is shown to 
accelerate immune aging (27).  Additionally, CD4+ T cells in older individuals are 
impaired in their ability to effectively activate B cells following vaccine, thereby 
reducing antibody production (28-31). 
Taken together, these data support the hypothesis that malfunctions in T cell signaling 
in older individuals play a role in a weakened immune response.   The need to understand 
how T cells activate and differentiate with age is important in determining when and 
where T cell function is impaired.  The present study examines the effects of different 
costimulation of CD4+ naïve T cells from older individuals on T cell activation and 
differentiation. 
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Materials and methods 
Antibodies and Reagents 
Hybridomas expressing anti-CD11a (HB202), and anti-CD54 (R6.5D6) were purchased 
from American Type Culture Collection (ATCC, Rockville, MD) and purified from 
serum-free culture medium with protein G-sepharose (Amersham Pharmacia, Piscataway, 
NJ).  Anti-CD28 (clone ANC28.1) was purchased from Ancell (Minneapolis, MN) and 
anti-CD3 (OKT3) was purchased from eBioscience (San Diego, CA).  Anti-CD11a-
FITC, anti-CD3-FITC, anti-CD25-FITC, anti-CD27-PE, anti-CD134-PE, anti-CD54-PE, 
anti-CD28-TriColor, anti-CD45RA-TriColor and anti-CD45RO-TriColor were purchased 
from Caltag Laboratories (Burlingame, CA).  Anti-CD25-TriColor (Caltag) and anti-
CD25-PE-Cy5 (Becton Dickenson, San Jose CA) were used interchangeably with similar 
results.  Foxp3 was detected using the Anti-Human Foxp3 Staining Set (eBioscience) in 
both FITC and PE, and used interchangeably with anti-Foxp3-PE (Miltenyi Biotec Inc., 
Auburn, CA) with similar results.   Anti-CD137-PE-Cy5, anti-CD154-FITC, Annexin V-
PE and 7-AAD were purchased from BD Pharmingen.  CFSE (5-(and-6) 
carboxyfluorescein diacetate, succinimidyl ester) was purchased from Molecular Probes 
(Eugene, OR) and used at 2.5 µM in labeling experiments.   
 
Cell Purification 
Naïve human CD4+ T cells were isolated from peripheral blood of multiple donors by 
negative selection using a naïve T cell enrichment kit (Stem Cell Technologies, 
Vancouver, BC, Canada) as we have reported previously (15,16).  All magnetically 
selected naïve CD4+ T cell populations were of >98% purity as assessed by flow 
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cytometry.  In the present work, purified naïve human T cells represents cells that are 
CD4(+) CD45RA(+)RO(-) CD11alo CD27(+).  Isolation of T cells with a differentiated 
phenotype was accomplished by negative selection of stimulated populations with 
antibodies against CD45RA and CD27 (Stem Cell Technologies), resulting in T cells 
with a CD4(+) CD45RA(-) CD11ahi CD27(-) phenotype.  
 
T cell Stimulation 
Antibodies in PBS were attached to tissue culture-treated plates (Midwest Scientific, St. 
Louis, MO) by incubation at 37°C for 2 hours or overnight at 4°C, and wells were 
washed three times with PBS to remove unbound antibody.  Naïve CD4+ T cells were 
added at a concentration of 1x106-2×106 / ml, and stimulated with 1 µg/ml anti-CD3 plus 
10 µg/ml anti-ICAM-1, or 5 µg/ml anti-LFA-1, or 5 µg / ml anti-CD28.  Optimal 
antibody concentrations were determined based on the minimum dose that led to 
maximum T cell proliferation (not shown).   
 
Flow Cytometry 
Flow cytometry was performed using the FACScan (Becton Dickenson, San Jose CA) or 
the Accuri C6 Flow Cytometer System (Accuri Cytomoters, Ann Arbor MI).  The 
FACScan was calibrated using CaliBRITE beads (Becton Dickinson), and the Accuri C6 
was calibrated using Sphero APC Calibration Particles (Spherotech, Inc. Lake Forest, 
IL).  This was supplemented by compensation using singly stained cells.  Data were 
analyzed using Cell Quest (Becton Dickinson), FlowJo (Tree Star Inc, Ashland, OR) and 
CFlow (Accuri Cytometers). 
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Measurement of cell proliferation and apoptosis 
After stimulation, naïve CD4(+) T cells were harvested on the days indicated and stained 
with AnnexinV-PE and 7-AAD at 2 µg/ml prior to flow cytometric analysis.  Viable cell 
number was quantified by comparing the number of non-apoptotic or non-necrotic cells 
[AnnexinV(-) and 7-AAD(-)] acquired on the flow cytometer during one minute at a 
constant flow rate.  Calibration standards of known cell concentrations were used to 
calculate the number of viable cells within each population.  To measure the induction of 
apoptosis, CFSE-labeled cells were stained as indicated above and the numbers of 
apoptotic cells were determined [apoptotic cells are designated as AnnexinV(+) and 7-
AAD(-)].  The data shown are the percentage of apoptotic cells within each cell 
generation. 
 
Statistical analysis. 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, 
CA.) or SigmaStat (Systat Software Inc. San Jose, CA).  Statistical tests and significance 
for individual figures are indicated in figure legends. 
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Results 
Characterization of resting peripheral T cells and CD4+ naïve T cells in older 
individuals. 
 Healthy young individuals express CD28 on the surface of their naïve CD4+ T 
cells as well as low levels of ICAM-1 (32).  Their naïve T cells also express the 
chemokine receptor CCR7 and L-selectin CD62L.  Both of these promote homing into 
lymph nodes (33).  Our data support the high expression of CCR7 and CD62L on naïve 
CD4+ T cells in young individuals (Fig 5.1).  We characterized surface molecule 
expression on both naïve and peripheral T cells from older individuals.  T cells 
represented about 48% of total peripheral blood mononuclear cells (PBMC) and of those 
T cells, 45% were CD45RO+ non-naive, 63% were naïve-like and about 7% were a 
memory-like phenotype (Fig. 5.2).   Seventy-three percent of the T cells were CD4+, 
25% were CD8+ and we observed a small population of T cells, averaging about 6%, that 
expressed both CD4 and CD8 (Fig. 5.2).   As in young subsets, resting T cells from older 
individuals expressed a low level (10 %) of CD54 (ICAM-1), 80% of the cells were 
CD28 positive and 9% of T cells were double positive for both CD54 and CD28 (Fig. 
1B).  Lymph node homing molecule CCR7 was expressed on about 65% of T cells from 
older individuals while 85% were positive for CD62L; almost all of the CCR7+ cells 
(60%) were also double positive for CD62L (Fig. 5.2).   
 The purity of the apparently naïve CD4+ T cells that were used to characterize the 
resting naïve phenotype averaged 92% once isolated from PBMC of elderly donors using 
negative magnetic selection (Fig. 5.3).  This was consistently lower than the apparent 
purity observed many times with younger subjects (98%) and suggests an as yet 
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described basic young/old difference.  CD54 expression was just slightly lower on naïve 
cells (8%) of older individuals than on total T cells, CD28 expression (85%) was slightly 
higher on naïve cells from older subjects while only 5% expressed both CD54 and CD28 
(Fig. 5.3).  Naïve cells that expressed CCR7 were reduced to about 77% compared to 
CCR7 expression (98%) on CD4+ naïve T cells from younger individuals (Fig. 5.1) 
while CD62L expression remained high (91%) and almost all of the cells that were 
positive for CCR7 were also positive for CD62L (Fig. 5.3). 
 Naïve T cells are thought to be largely homogeneous in phenotype and multi-
potent in the ability to differentiate.  It should be noted here that at low expression levels, 
percent positive cell populations are delimited by the gating procedures and control 
measures to establish non or low expressing populations.  Hence cells excluded for 
CD54, for example, may still be positive for CD54 but simply express CD54 at a level 
that falls below the limit of detection with flow cytometry.  These data should not be 
interpreted as supporting the hypothesis of naïve T cell subsets.  Figures 5.4, 5.5 shows 
the histogram plots that correspond with Figures 5.2 and 5.3.  These plots illustrate the 
subsets present for molecules on the surface of total T cells compared to the 
homogeneous shift in fluorescence intensity that correlates with an increase in surface 
molecule expression observed in the naïve plots.  
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Figure 5.1 
Figure 5.2 
Figure 5.3 
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T cell surface molecule expression 
CD4+ naïve T cell surface molecule expression 
Figure 5.4 
Figure 5.5 
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Figure 5.1-5.5. Characterization of resting peripheral T cells and CD4+ naïve T cells in 
older individuals.  5.1) Percent positive CCR7 and CD62L cells in freshly isolated CD4+ 
naïve T cells isolated in healthy young individuals.  CCR7 n=9. CD62L n=6.  5.2) 
Phenotype of T cells from older individuals at day 0.  PBMCs were isolated from 
peripheral blood and T cells were gated via CD3 expression.  Naïve-like cells were 
CD11a(-) and CD27+, and memory-like cells were CD11a+ and CD27(-.)  Other 
phenotypes were determined by expression of CD4, CD8, CD54, CD28, CCR7 and 
CD62L.  n=4.    5.3) Phenotype of CD4+ Naïve T cells from older individuals at day 0.  
5.4) Histogram plots of T cell surface molecule expression. 5.5) Histogram plots of 
CD4+ naïve T cell surface molecule expression. Black like is unstained control and red 
line is surface fluorescence. Naïve cells were isolated using a negative selection magnetic 
column and purity was determined by percent expressing a naïve phenotype (CD45RO(-), 
CD11a(-), CD27+).  Naïve cell phenotype was verified by cell surface expression of 
CD54, CD28, CCR7 and CD62L.  n=4
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Kinetic expression of tertiary costimulatory molecules following activation of CD4+ 
naïve T cell from older individuals is unregulated compared to that of younger 
individuals. 
 To study how activation of naïve CD4+ T cells and progression from naïve to 
effector and memory phenotypes might differ between younger and older individuals, we 
measured the expression of cell surface tertiary costimulatory molecules.  Tertiary 
costimulatory molecules help to promote T cell differentiation, effector function and 
survival.  CD40L, OX40 and 4-1BB are tertiary costimulatory molecules that are only 
expressed on activated T cells and are important in propagating T cell responses to 
memory.  We wanted to initially characterize the kinetic expression of each tertiary 
costimulatory molecule on CD4+ T cells from healthy young individuals as they went 
from naïve to effector or memory phenotype with stimulation through different second 
signals.  This characterization would help to define which molecules stayed on or were 
turned on then off as the cells progressed through activation and which molecules are 
able to receive third signals to direct cells to effector or memory (Fig. 5.6).   Naïve CD4+ 
T cells that were stimulated through CD3+CD28 (red diamonds) experienced 
intermediate expression of all three tertiary signals that peaked at around 30% to 40% 
positive by day 7 and began to decline to day 11.   Costimulation through LFA-1 
(CD11a) (green squares) induced the highest expression of all three tertiary signaling 
proteins and, similar to CD28 costimulation, peaked at 7 days before a slight decline in 
OX-40 and 4-1BB and a more drastic decline in CD40L (Fig. 5.7).  Unlike costimulation 
through CD28 or LFA-1, stimulation through CD3+ICAM-1 (blue triangles) activated the 
tertiary costimulatory molecules with slower responses but did not plateau during the  
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Figure 5.6, 5.7.  Costimulation of naïve CD4+ T cells from younger individuals through 
ICAM-1 induces different kinetics of expression of tertiary stimulatory molecules 
compared with costimulation through CD28 or LFA-1.  5.6) Schematic representation of 
possible tertiary costimulatory molecule timeline expression as a naïve cell activates and 
differentiates.  Arrows indicate points where tertiary signals that are turned on can 
receive a signal to propogate differentiation to a memory phenotype.  5.7) Cell surface 
expression of tertiary costimulatory molecules, CD40L, OX-40 and 4-1BB, at day 0 and 
3, 5, 7, and 11 days after stimulation through either CD3, CD3+ICAM-1, CD3+LFA-1, 
CD3+CD28 or cells left unstimulated. Error representated at SD. n=3.
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studied time interval and continued increasing through 11 days after stmulation to a 
higher expression than costimulation through CD28 (Fig. 5.7).  As expected, stimulation 
through the TCR (CD3) alone or cells that were left unstimulated exhibited low or no 
increase in CD40L, OX-40 or 4-1BB positive cells, respectively (Fig. 5.7). 
 Kinetic expression of CD40L, OX-40 and 4-1BB on stimulated CD4+ cells 
differed vastly in pattern of expression between older and younger individuals as well as 
among different older subjects.  CD4+ T cells from individual “A” showed and 
immediate and high expression of all tertiary costimulatory molecules by day 3 of 
stimulation through CD3+LFA-1 (green squares) that declined slightly to day 10 whereas 
costimulation through CD28 or ICAM-1 gave lower expression of tertiary costimulatory 
molecules that peaked at day 5 for CD28 (red diamonds) and was delayed but still 
increasing to day 10 with ICAM-1 (blue triangles) (Fig. 5.8).  Individuals “B” and “C” 
expressed low levels of CD40L with costimulation through CD28 or ICAM-1 that 
continued to rise through day 10 with CD28 stimulated cells only (Fig. 5.8).  OX-40 and 
4-1BB positive cells were greater for individual “B” when costimulated through ICAM-1 
but peaked at days 5 and 7, respectively, where cells costimulated through CD28 began to 
plateau in expression from days 3-10 (Fig. 5.8).  OX-40 and 4-1BB expression were also 
greater with cells costimulated through ICAM-1 for individual “C”, however OX-40 
expression peaked at day 5 for both CD28 and ICAM-1 cells whereas 4-1BB continued to 
rise in expression for both stimulations (Fig. 5.8).   Costimulation through CD28, LFA-1 
or ICAM-1 induced a quick and high expression of all three tertiary costimulatory 
molecules for individual “D” that peaked at day 7 for CD28 stimulated cells and 
remained constant or increased for cells stimulated through LFA-1 or ICAM-1 (Fig. 5.8).   
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Figure 5.8 
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Figure 5.8.  Costimulation of naïve CD4+ T cells from 4 older individuals through 
ICAM-1 generated different expression patterns for tertiary stimulatory molecules.  Cell 
surface expression of tertiary costimulatory molecules, CD40L, OX-40 and 4-1BB, at day 
0 and 3, 5, 7, and/or 10 days after stimulation through either CD3, CD3+ICAM-1, 
CD3+LFA-1 or CD3+CD28.  Number of stimuli and frequency of days that tertiary 
cosimulatory molecule expression was measured was dependent on the amount of naïve 
cells able to be isolated.  
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Stimulation through the TCR (CD3) alone unexpectedly led to a slight increase in 
CD40L, OX-40 and 4-1BB in individual “D”.  Taken together, these data suggest that 
activation and expression of tertiary costimulatory molecules is inconsistent in stimulated 
T cells from older individuals as compared with our observation of relatively consistent 
responses in cells from younger individuals (Fig. 5.7). 
 
ICAM-1 costimulation of naïve CD4+ T cells from older individuals does not confer a 
regulatory T cell phenotype in contrast to T cells from younger subjects. 
 Previous work from our lab and published by Kelli Williams, et al. demonstrates 
that costimulation in the absence of exogenous cytokines of CD4+ naïve T cells through 
ICAM-1 but not CD28 or LFA-1 can lead to a regulatory T cell phenotype capable of 
suppressive function in vitro (15).  To further compare differentiation of naïve CD4+ T 
cells between older and younger individuals we looked for the ability of naïve CD4+ T 
cells from older individuals to develop into a regulatory T cell phenotype.  Representative 
dot plots provided by Kelli Williams of Treg markers, Foxp3 and CD25, indicate that 
costimulation of naïve CD4+ T cells from older individuals through either CD28 or 
ICAM-1 did not induce differentiation to a regulatory phenotype greater than baseline 
(CD3 alone) (Fig. 5.9).  Compiled averages of percent Foxp3hiCD25+ cells are shown in 
Figure 5.10.  Costimulation of naïve CD4+ T cells through CD28 does not induce a 
sizable Treg population, similar to that in young individuals (Fig. 5.10).  However, unlike 
differentiation of CD4+ T cells from younger individuals, costimulation of naïve CD4+ T 
cells from older individuals through ICAM-1 no longer seems able to induce a significant  
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Treg population under these circumstances (Fig. 5.10).  This suggests that certain 
activation and differentiation functions differ or decline with age. 
 
Costimulation of naïve CD4+ T cells from older individuals through CD3+ICAM-1 
generated a memory phenotype in contrast to costimulation through CD3+CD28. 
 The differences in activation/differentiation of CD4+ naïve T cells from older 
individuals compared to younger may give some insight to the inability to effectively 
fight disease and respond to vaccine as we age.  Since naïve CD4+ T cells from older 
individuals do not differentiate to a regulatory phenotype when costimulated through 
ICAM-1 in contrast to the situation with younger individuals, we wanted to investigate 
the possibility that those same naïve T cells would be able to differentiate into an 
alternate memory phenotype.  In Figure 5.11 cells that were stimulated through 
CD3+LFA-1 divided but did not differentiate efficiently and did not express any memory 
phenotype cells (lower right quadrant).  The lack of memory phenotype in cells 
costimulated through LFA-1 mimics the outcome of costimulation through LFA-1 in 
cells from young individuals.  However, in older individuals we observed diminished 
differentiation to effector as well.   
         Costimulation of CD4+ naïve T cells from older individuals through CD28 induced 
differentiation that does not follow the dogma established in young subjects and produced 
effector (upper right quadrant) but not memory cells by day 14 (Fig. 5.11).  In contrast, 
CD3+ICAM-1-stimulated naïve cells from older individuals proliferated and 
differentiated into both effector and memory phenotypes similar to the response observed 
in ICAM-1 costimulated naïve cells from younger individuals (Fig. 5.11).   When these  
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Figure 511-5.13. Costimulation of naïve CD4+ T cells from older individuals through 
CD3+ICAM-1 generated a memory phenotype in contrast to costimulation through 
CD3+CD28.  5.11) Representative dot plot of memory cell phenotypes after 14 days.  
Naïve T cells from older individuals were left unstimulated or stimulated though 
CD3+LFA-1, CD3+ICAM-1 or CD3+CD28.  Cells are gated on CD45RO+ and memory 
phenotype is CD11a+, CD27(-).  5.12) Number of memory cells quantified after 14 days 
of stimulation. 5.13) Percent of total cells that are memory after 14 days of stimulation. 
Data represented as mean ± SEM, *p<0.05 using two tail t-Test.  n=4, CD3; n=6 
CD3+ICAM-1 and CD3+CD28; n=3, CD3+LFA-1.  
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data are quantified, the total number of memory T cells produced from costimulation 
through ICAM-1 is significantly greater than those produced by CD28 (Fig. 5.12).  When 
looking at the percent of memory cells at day 14 of culture, minimal difference was 
observed between the cells costimulated through CD28 and ICAM-1 (Fig 5.13) which 
does not agree with the number of memory cells produced (Fig. 5.12).  The discrepancy 
is due to a lower number of total cells alive at day 14, therefore skewing the memory 
percentages.  This will be discussed further in the next section.  Cumulatively, these data 
suggest that although naïve CD4+ T cells from older individuals do not stimulate or 
differentiate in a similar manner to cells stimulated from younger individuals, only 
costimulation through ICAM-1 could produce a T cell phenotype capable of exhibiting 
memory characteristics.   
 
Costimulation of Naïve CD4+ T cells from older individuals through ICAM-1 increases 
viable cell counts compared to other stimuli.  
 For young individuals, naïve CD4+ T cells costimulated through CD28 or 
ICAM-1 but not LFA-1 are protected from apoptosis (10, 14, 13).  The discrepancy 
between percent and numbers of memory cells from Figures 5.12 and 5.13 led us to 
investigate cell numbers being produced, proliferation and apoptosis of CD4+ naïve T 
cells from older individuals following costimulation through ICAM-1, LFA-1 and CD28.  
Cell counts were taken at 0, 5, 7, 10 and 14 days after stimulation and, as expected with 
our control, stimulation through the TCR (CD3) alone led to a consistent decline in cell 
number (Fig. 5.14).  Costimulation of naïve cells through LFA-1 maintained cell 
numbers, and costimulation through ICAM-1 gave the only increase in cells through 14  
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Figure 5.14 
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Figure 5.14.  Costimulation of Naïve CD4+ T cells from older individuals through 
ICAM-1 increases viable cell counts compared to other stimuli.  Naïve CD4+ T cells 
from older individuals were stimulated through CD3, CD3+ICAM-1, CD3+LFA-1 or 
CD3+CD28 and cell numbers were enumerated at days 0, 5, 7, 10 and 14.  Cell counts 
were done using flow cytometry.  Live cells were gated on and cell numbers were 
determined based on a known number of polystyrene counting beads in the sample at the 
time of analysis.  n=5 for days 7 and 14; n=3 for days 5 and 10.  
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days of stimulation (Fig. 5.14).  Interestingly, costimulation of CD4+ naïve T cells 
through CD28 led to a consistent decline in cell numbers, similar to stimulation through 
the TCR alone (Fig. 5.14).  This finding contradicts what is known for cells stimulated 
through CD28 from young individuals and explains the low total memory cell number 
compared to the percent in Figure 5.12.  Since memory cells are long lived and effector 
cell numbers contract following an immune response, the few memory cells produced by 
the CD28 costimulation skewed their percent of the total population as effector and naïve 
cells died.   
 
Preliminary data:  Costimulation of Naïve CD4+ T cells from older individuals through 
ICAM-1 leads to increased cells at 2 and 3 divisions and protection from apoptosis up to 
4 divisions. 
          To decipher whether the lower cell counts from Figure 5.14 were due to lack of 
proliferation or cell death, CFSE dilution and AnnexinV expression were characterized.  
Proliferating cells that have been stained with CFSE will dilute the amount of CFSE 
within the cell by 50% for each cell division.  This allows for individual divisions to be 
quantified and when co-stained with AnnexinV the percent of apoptotic cells in each 
division can also be determined.  As a control, stimulation through the TCR (CD3) alone 
did not induce much cell division with the majority of the cells remaining undivided (Fig. 
5.15); as well, the few cells that did divide were highly apoptotic, especially in divisions 
1-3 (Fig. 5.16).  Naïve CD4+ T cells from older individuals that were stimulated through 
CD3+LFA-1 (hatched bars) underwent a high level of proliferation, peaking at 2 and 3 
divisions (Fig. 5.15), yet those cells were also highly apoptotic in undivided cells as well  
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Figure 5.15, 5.16. Preliminary Data: Costimulation of Naïve CD4+ T cells from older 
individuals through ICAM-1 leads to increased cell numbers at 2 and 3 divisions and 
protection from apoptosis up to 4 divisions.  Naïve CD4+ T cells from older individuals 
were stained with CFSE and stimulated through CD3, CD3+ICAM-1, CD3+LFA-1 or 
CD3+CD28.  At day 7, cells were stained with AnnexinV and analyzed using flow 
cytometry.  5.15) CFSE dilution was analyzed and the percent of cells in cach division 
was calculated based on the total population.  5.16) AnnexinV positive cells were 
calculated against cell division to determine the percent of apoptotic cells in each cell 
division.  n=1.
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as all divisions examined (Fig. 5.16) which remains consistent with the maintained and 
level cell counts from Figure 5.14.  Cells that were costimulated through CD28 (filled 
bars) exhibited a moderate level of cellular division that peaked at 3 and 4 divisions (Fig. 
5.15) but displayed a high level of apoptosis, particularly for divisions 1-3 (Fig. 5.16).  
This observation explains that the low cell count from Figures 5.12 and 5.14 was not due 
to lack of proliferation but rather the inability to protect the activated cells from 
apoptosis.  Costimulation of naïve CD4 T cells from older individuals through ICAM-1 
(open bars) led to a substantial level of proliferation (Fig. 5.15), peaking at 2 and 3 
divisions, that were also protected from apoptosis in a manner greater than cells 
costimulated through either LFA-1 or CD28 for the vast majority of cell divisions (1-4) 
(Fig. 5.16).  Taken together, these preliminary data suggest that costimulation of naïve 
CD4+ T cells from older individuals through ICAM-1 leads to proliferation and 
protection from cell death that contributes to a collective increase in cell number over 
time and that ICAM-1 might function better as a costimulator during immunosenescence 
than do either CD28 or LFA-1. 
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Discussion 
 Age related decline of the immune system can be attributed to numerous factors 
including but not limited to changes in T cell subsets, impaired function of those subsets, 
decreased thymic output and a T cell compartment that harbors quiescent or semi-
quiescent cells (34-36).  In the current study, we aimed (i) to define and compare the total 
T cell and naïve T cell subsets in older individuals and (ii) characterize their activation 
and differentiation from naïve T cells using a system of stimulation that we have defined 
extensively in young subsets (15,16).  Our overall goal was to investigate and design new 
strategies to promote an effective and functional T cell compartment in the elderly.   
  
          The primary decrease in expression of the naïve marker CD45RA within the total T 
cell population occurs before the age of 30 (especially in CD4+ cells); and between the 
ages of 30 to 65, CD45RA expression only decreases slightly (37).  Our observations 
support the presence of a sizable naïve population in older people as seen in figure 1.  
The majority of naïve phenotype cells in the elderly, however, are not thymus derived.  
The naïve cell numbers are maintained by antigen-independent proliferation without 
differentiation leaving the majority of the naïve population (over 95%) being 
proliferation derived (1).  Naïve cells from healthy young individuals circulate between 
the periphery and lymph nodes using cell surface molecules CCR7 and CD62L (33).  Our 
data show a decrease in CCR7 expression on CD4+ naïve T cells.  This decrease has also 
been observed in aging mice and leads to an age related decrease in lymphocyte 
migration to secondary lymphoid organs (38-40).   Our data also show that as is the case 
in young subjects, naïve T cells from older individuals express a low level of ICAM-1 on 
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their surface and as previously documented CD28 is slightly downregulated.  However, 
the expression of CD28 was lower on the total T cells that we examined compared to the 
CD4+ naïve T cells.  This observation is consistent with the fact that loss of CD28 is 
more prominent in CD8+ T cells than CD4+ cells (41).  Loss of CD28 on CD4+ T cells 
has been correlated with a decreased autocrine proliferative capacity as well as altered 
cytokine secretion (42,43) 
Due to the dramatic decrease of recent thymic emigrants in older individuals it is 
important to characterize the ability of these cells to activate and differentiate.  
Measurement of tertiary costimulatory molecule expression facilitates in the assessment 
of how cells are progressing toward differentiation with respect to function.  CD40L 
increases T cell proliferation and cytokine secretion (44), OX-40 serves to prolong T cell 
division increase cell survival and increase memory cell development (45,46) and 4-1BB 
can induce IL-2 production and sustain cell activation (47,48).   The irregularly regulated 
patterns of expression of CD40L, OX-40 and 4-1BB that we observed in older 
individuals suggest that not only do naïve T cells from older individuals activate 
differently than in young but differentiation may be impaired or skewed as a result.   
In our stimulation system we observe a dramatic difference in differentiation of naïve 
cells from younger to older individuals.  Unlike young subjects, stimulation of naïve T 
cells from older individuals through CD3+ICAM-1 did not induce differentiation to a 
regulatory phenotype.  This is of interest because it has been reported that regulatory T 
cells accumulate in the elderly and impair effective immune responses to infection and 
disease (49).   
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Naïve CD4+ T cells from older individuals also differentiate to a memory phenotype 
unlike of the case with younger individuals because only costimulation through ICAM-1 
will generate memory cells in high numbers.  This suggests that even though CD28 is 
present on most of the CD4+ naïve T cells from older individuals, costimulation through 
CD28 is not capable of initiating efficient differentiation to either a regulatory or memory 
phenotype.   
In addition to impairment of differentiation, costimuation of CD4+ naïve T cells from 
older individuals through LFA-1 or CD28 was not able to maintain a healthy, viable cell 
population.  Costimulation through ICAM-1 was able to increase total cell numbers, drive 
cells to proliferation and largely protect them from apoptosis.  In contrast, costimulation 
through LFA-1 or CD28 could induce proliferation but not protect the cells from 
apoptosis, thus not maintaining cell numbers as effectively as ICAM-1.  Without 
effective expansion of the differentiated T cell population, naïve T cells from older 
individuals cannot carryout specific immune functions. 
 In summary, we have shown that CD4+ Naïve T cells from older individuals have 
a slightly different phenotype from naïve cells in younger individuals.  Naïve cells from 
older individuals activate and differentiate into specific T cell subpopulations differently 
than similar cells in young individuals and the activation process is not regulated in the 
same manner as it is in young.  Costimulation of CD4+ naïve T cells from older 
individuals through LFA-1 induces activation that does not lead to differentiation or 
protection from apoptosis.  Similarly, costimulation of the same naïve T cells through 
CD28 does not always give efficient activation as determined by expression of tertiary 
costimulatory molecules and does not lead to cell differentiation or survival.  However, 
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CD4+ naïve T cells from older individuals can proliferate, differentiate to a memory 
phenotype and are more protected from apoptosis when costimulated through ICAM-1.  
Taken together, these data suggest that costimulation through ICAM-1 can provide 
signals to aging naïve T cells that might be more functional or effective than signals 
through other signaling molecules.  Due to the senescence of the immune system and 
increased incidence of disease as we age, it is imperative to investigate alternative 
strategies for reinstituting T cell immune responses to new antigens.  ICAM-1 as a T cell 
costimulatory molecule may provide new methods and understanding of our ability to 
maintain an effective immune system as we get older, and may suggest new targets for 
interuption in immune suppression. 
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Chapter 6 
Stimulation methods to generate murine memory T cells using ICAM-1 
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Introduction 
 As with CD4+ naïve T cells from humans, mouse cells also require two signals to 
become fully activated and differentiate.  Costimulation of murine naïve T cells through 
CD28 has been widely studied, and many of the differentiation to memory studies have 
been done in mice.  CD28 expression, function, sequence and gene expression are closely 
related between human and mice (1, 2).  Studies of CD28 costimulation in mice 
demonstrate that the costimulatory molecule plays roles in differentation to a memory 
and regulatory T cell population (3, 4).   
 The role of ICAM-1 as a costimulatory molecule of CD4+ T cells or CD4+ naïve 
T cells has not yet been defined in mice.  The ICAM-1 molecule is not completely 
conserved among species and although our lab has previously defined ICAM-1 as a 
costimulatory molecule on human CD4+ naïve T cells its function may differ in mice.   
The sequence of ICAM-1 is not highly conserved between human and mice, exhibiting 
only 50% protein and 65% DNA homology (5).  Additionally, genomic blots of human 
DNA exhibited no hybridization when probed with murine ICAM-1 cDNA and ICAM-
1:LFA-1 interactions do not occur between species indicating that the ICAM-1 gene is 
poorly conserved throughout evolution (5, 6).   The cytoplasmic tail of human ICAM-1 
contains a Src-homology (SH3) binding domain that is not conserved in mice, therefore 
the intracellular signaling may occur differently in mice than human and have different 
outcomes.   
 In this chapter, we aim to employ the same in vitro ICAM-1 costimulation system 
that we have characterized with CD4+ T cells and CD4+ naïve T cells in human with 
mouse cells to determine, despite ICAM-1 differences, if they can differentiate in a 
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similar manner with similar resulting phenotypes.  Our goal is to describe the different 
methods that we use to costimulate mouse T cells through ICAM-1 and the outcomes that 
are observed.  The ability to differentiate T cells from mice with ICAM-1 could provide 
useful tools in mouse disease models and development possible immunotherapies.  The 
data presented here represent half of a manuscript written in conjunction with Kelli 
Williams of the Benedict lab.
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Methods and materials 
Mice  
Male Balb/c mice (Jackson Laboratories, Bar Harbor,ME) were obtained at 6 weeks 
of age. Animal experiments were performed with approval from the University of Kansas 
Animal Care and Use Committee. 
 
Antibodies and Reagents 
          Anti-CD44-PECy5, anti-CD127-PE and anti-CD69-FITC were all purchased from 
Becton Dickenson (San Jose, CA).  Anti-CD62L-FITC and anti-CD69-PE were 
purchased from Caltag Laboratories (Burlingame, CA).  Anti-CD3 clones 145-2C11, 
500A2; anti-ICAM-1 clone 3E2; and anti-CD28 clone 37.51 were purchased from Becton 
Dickenson.  Anti-CD3 clone C363.29B was purchased from Southern Biotech 
(Birmingham, Alabama). Anti-ICAM clones YN1 (YN1/1.7.4) and KAT-1 were 
purchased from eBioscience (San Diego, CA).  Anti-ICAM-1 clone R6.5D6 (R6.5) was 
purchased from BioXCell (West Lebanon, NH).  Mouse recombinant IL-2 and anti-
ICAM-1 clone 166623 were purchased from R&D Systems (Minneapolis, MN).  Anti-
CD3 clone KT3 and anti-ICAM-1 clone 3E2B were purchased from Chemicon 
International (Temecula, CA).  Anti-ICAM-1 clone BE29G1 was purchased from 
Biodesign International (Saco, ME).    
 
Description of stimulating antibodies 
 145-2C11:  Hamster anti-mouse monoclonal CD3 antibody that binds to the 
epsilon chain and shares properties with OKT3 (the CD3 antibody used in our human 
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stimulations in vitro) (7).  KT3: Rat anti-mouse monoclonal CD3 antibody that binds to 
the epsilon chain (8).  500A2:  Hamster anti-mouse monoclonal CD3 antibody that binds 
to the epsilon chain (9).  C363.29B:  Rat anti-mouse monoclonal CD3 antibody that binds 
to the epsilon chain.  3E2B: Hamster anti-mouse monoclonal ICAM-1 antibody (10).  
BE29G1:  Rat anti-mouse monoclonal ICAM-1 antibody (11).  3E2:  Hamster anti-mouse 
monoclonal ICAM-1 antibody (12).  166623: Rat anti-mouse monoclonal ICAM-1 
antibody (13).  YN1: Rat anti-mouse monoclonal ICAM-1 antibody (14).  R6.5D6 
(R6.5): mouse anti-human monoclonal ICAM-1 antibody was tested for possible cross 
reactivity with mouse ICAM-1 (15).  KAT-1: Rat anti-mouse monoclonal ICAM-1 
antibody (16) 
 
Cell Purification 
Spleens were harvested from Balb/c mice between 8 and 12 weeks of age, minced and 
repeatedly pressed with a 1cc syringe plunger through a sterile 70 µm nylon mesh cell 
strainer.  Erythrocytes were cleared by a five-minute incubation of the cell suspension in 
ACK lysis buffer (0.15M NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA, pH 7.2) at 37oC.  
CD4+ T splenocytes were isolated from spleens of Balb/c mice by negative selection 
using a CD4+ T cell enrichment kit (Stem Cell Technologies, Vancouver, BC, Canada).  
Naïve CD4+CD62L+ T cells were further purified by a positive selection using CD62L 
microbeads (Miltenyi Biotec, Auburn, CA).  CD5+ T cells were separated from total 
splenocytes using CD5 positive selection microbeads also from Miltenyi Biotec.  
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Cell Stimulation 
Antibodies in PBS were attached to 96 well tissue culture plates (Midwest 
Scientific, St. Louis, MO) by incubation at 37oC for two hours and plates were washed 
three times with PBS before the addition of splenocytes.  Stimulatory antibody clones and 
concentrations are indicated in figures and text. All cells were stimulated at a 
concentration of 2x106 cells/ml. 
 
Flow Cytometry 
Flow cytometry was performed using the FACScan (Becton Dickenson, San Jose CA) 
and was calibrated using CaliBRITE beads (Becton Dickinson).  This was supplemented 
by compensation using singly stained cells.  Data were analyzed using Cell Quest 
(Becton Dickenson).   
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Results 
Titration of stimulating antibodies	  on Balb/c CD4+ T splenocytes to induce optimal 
CD69 expression 
 The initial goal of finding the appropriate concentration of stimulating antibodies 
was to verify that we were inducing CD4+ T cell activation by the induction of CD69 
expression.  CD69 is a well studied early activation marker that is expressed within hours 
of stimulation (17).  We titrated anti-CD3 alone, anti-CD3 with 2.5ug/mL of anti-CD28, 
and CD3 with anti-ICAM-1.  Our goal was to find a concentration of anti-CD3 that 
would initiate expression of CD69 but would induce full CD69 expression when anti-
CD3 was used in conjunction with anti-ICAM-1.  That would verify that any 
differentiation was due to the effect of ICAM-1 costimulation and not just because of a 
TCR trigger.  Four clones of anti-CD3 were tested at 4, 5 or 6 concentrations.  Anti-CD3 
clones 145-2C11 and 500A2 behaved similarly in terms of their ability to induce CD69 
expression because 0.01 ug/mL-0.1 ug/mL gave increasing CD69 positivity and 0.5 
ug/mL, 1 ug/mL (and 2 ug/mL with 500A2) gave similar and close to maximum CD69 
expression (Fig. 6.1).  Anti-CD3 clones KT3 and C363.29B yielded a lower activation 
response compared to 145-2C11 and 500A2 and both generated under 70% CD69 
positive cells with an anti-CD3 concentration of 2 ug/mL (Fig. 6.1).  In general, the MFI 
of the CD69 positive population mimicked the percent expression patterns.  Stimulation 
with anti-CD3 clones 145-2C11 and 500A2 exhibited an increasing CD69 expression 
with increasing anti-CD3 concentrations, peaking at an MFI of 200 with 1 ug/mL each 
(Fig. 6.2).  As with percent expression, CD69 MFI was slightly lower with KT3 and  
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Figure 6.1 
Figure 6.2 
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Figure 6.1-6.2. Titration of stimulating CD3 antibodies	  on Balb/c CD4+ T splenocytes to 
induce optimal CD69 expression.  CD4+ T splenoctyes were stimulated for 12 hours 
using CD3 antibody clones and the concentrations indicated. Percent CD69 positive and 
(6.1) CD69 MFI (6.2) were determined using flow cytometry. 
	   225	  
C363.29B at each anti-CD3 concentration than 145-2C11 and 500A2.  Level of CD69 
expression increased with concentration of anti-CD3 but had not reached an MFI of 200 
with the highest concentration, 2 ug/mL, of clones KT3 or C363.29B (Fig. 6.2).   
 When we added costimulation through CD28 (2.5 ug/mL) we observe that the 
percent CD69 expressing cells closely resembled that of stimulation with anti-CD3 alone 
(Fig. 6.1, 6.3), however, the level of CD69 expression was increased with the addition of 
anti-CD28 (Fig. 6.4).  0.5 ug/mL of anti-CD3 clones 145-2C11 or 500A2 yielded an MFI 
of over 200 when costimulation through CD28 was added but 1 ug/mL was needed to 
achieve a similar MFI when using anti-CD3 alone (Fig. 6.2, 6.4).  Similar effects were 
also observed with clones KT3 and C363.29B (Fig. 6.2, 6.4).  The concentration of anti-
CD3 that was chosen for each clone depended on the lowest concentration to induce 
CD69 expression along with proliferation data that was performed by Kelli Williams 
(data not shown).  Upcoming experiments used 0.01 ug/mL of 145-2C11, 0.5 ug/mL of 
KT3, 0.05 ug/mL of 500A2 and 1ug/mL of C363.29B.   
 Five different clones of anti-ICAM-1 mouse antibodies (3E2B, BE29G1, 3E2, 
166623 and YN1) and one anti-ICAM-1 human antibody clone (R6.5) were tested for 
their ability to activate CD4+ T splenocytes from Balb/c by inducing expression of 
CD69.  All anti-ICAM-1 clones were tested at 1 ug/mL and 10 ug/mL.  Anti-CD3 clone 
145-2C11 did not induce CD69 expression when used in combination with any of the 
anti-ICAM-1 clones (Fig. 6.5).  Anti-CD3 clone KT3 activated a higher percent of CD4+ 
T cells with anti-ICAM-1 clones 3E2B, 3E2, YN1 and R6.5 (Fig. 6.5) but the level of 
CD69 expression of the positive population as measured by MFI was highest with 3E2, 
166623, YN1 and R6.5 (Fig. 6.6).  CD3 antibody clone 500A2 induced a similar level of  
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Figure 6.3 
Figure 6.4 
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Figure 6.3-6.4. Titration of stimulating CD3 antibodies with costimulation through CD28	  
on Balb/c CD4+ T splenocytes to induce optimal CD69 expression.  CD4+ T splenoctyes 
were stimulated for 12 hours using anti-CD3 clones and concentrations indicated in 
combination with costimulation through CD28 at 2.5 ug/mL. Percent CD69 positive and 
(6.3) CD69 MFI (6.4) was determined using flow cytometry. 
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CD69 positive cells (between 60% and 80%) as well as CD69 MFI (between 175 and 
225) with all anti-ICAM-1 clones (Fig 6.5, 6.6).  Anti-CD3 clone C363.29B activated the 
most T cells with ICAM-1 antibody clones 3E2B and 3E2 by measure of CD69 positive 
cells (Fig. 6.5), yet induced a higher CD69 MFI with 3E2 and 166623 (Fig. 6.6).  The 
two concentrations of anti-ICAM-1 antibodies induced very similar percent CD69 
positive and MFI of the CD69 positive population with all of the CD3+ICAM-1 
combinations with the exception of C363.29B+BE29G1 where the 10 ug/mL 
concentration of BE29G1 actually decreased CD69 positivity and level of expression 
(Fig 6.5, 6.6).  The ability of CD3 antibody clone 500A2 to activate all of the anti-ICAM-
1 clones with similar results, in addition to the proliferation results done by Kelli 
Williams (not shown), led us to select it as the CD3 stimulating antibody for 
differentiation experiments.  Since all of the ICAM-1 antibody clones activated CD4+ T 
cells to a similar degree with anti-CD3 500A2, we relied on the proliferation data (not 
shown) to select BE29G1 (10 ug/mL), 166623 (1 ug/mL) and R6.5 (10 ug/mL) for 
differentiation studies. 
 
Costimulation of CD4+ and CD4+CD62L+ splenocytes through ICAM-1 induces a 
memory phenotype. 
 With optimal anti-CD3 and anti-ICAM-1 concentrations determined, we wanted 
to establish whether costimulation of mouse CD4+ T cells and naïve (CD4+CD62L+) T 
cells through ICAM-1 could not only activate cells but also differentiate them to a 
memory phenotype.  Mouse central memory T cells are defined as CD44hi, CD127+, 
CD62L+.  CD4+ T cells purified from the spleens of Balb/c mice were stimulated  
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Figure 6.5 
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Figure 6.5-6.6. Titration of stimulating ICAM-1 antibodies	  on Balb/c CD4+ T 
splenocytes to induce optimal CD69 expression.  CD4+ T splenoctyes were stimulated 
for 12 hours through CD3 (145-2C11 at 0.1 ug/mL, KT3 at 0.5 ug/mL, 500A2 at 0.05 
ug/mL and C363.29B at 1 ug/mL) and costimulated through ICAM-1 clones and 
concentrations as indicated. The first bar of each ICAM-1 clone represents the 1ug/mL 
concentration and the second bar is the 10ug/mL concentration. Percent CD69 positive 
and (6.5) CD69 MFI (6.6) were determined using flow cytometry. 
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through CD3 (clone 500A2) plus various clones of ICAM-1 or CD28 for seven days and 
memory phenotype was determined.   Figure 6.7 illustrates the memory phenotype 
generated when CD4 T cells were costimulated through ICAM-1 (166623) or CD28 but 
not CD3 alone.  To quantify the percent of memory cells produced, cells were gated on 
the CD44hi population and the percent CD127+CD62L+ was determined.  Stimulation 
through CD3 alone yielded a baseline of about 7 percent memory phenotype while 
costimulation through ICAM-1 generated between 14 and 27 percent memory cells, 
depending on the costimulatory antibody clone, which closely resembled the 18 percent 
of memory seen after CD28 costimuation (Fig. 6.8).  Costimulation of naïve T cells 
through ICAM-1 generated 30 to 56 percent memory phenotype, depending on the 
antibody clone, whereas costimulation through CD28 gave only 14 percent memory 
phenotype and was very similar to the 12 percent generated by stimulation through CD3 
alone (Fig. 6.9).  Together, these data indicate that costimulation of murine CD4+ and 
naïve T cells through ICAM-1 can give rise to a memory cell phenotype that is similar or 
better than costimulation through CD28. 
 
Titration of CD3 (500A2) and ICAM-1 (purified and functional grade, KAT) stimulating 
antibodies and mouse IL-2 on CD5+ Balb/c splenocytes.  
 Since we were able to produce memory T cells with costimulation through 
ICAM-1 of CD4+ and CD4+ naïve T cells, we decided to see if we could reproduce those 
data with a starting CD5+ total T cell population and using the KAT-1 ICAM-1 clone.  
CD5 is a T cell marker that is highly expressed on mature T cells and is also found on a 
small subset of B cells (18).  The KAT-1 anti-mouse ICAM-1 clone has been used as a  
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Figure 6.7 
Figure 6.9 
Figure 6.8 
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Figure 6.7-6.9. Costimulation of CD4+ and CD4+CD62L+ splenocytes through ICAM-1 
induces a memory phenotype.  Stimulation through CD3 was done using 0.05 ug/mL of 
clone 500A2.  Costimulation through ICAM-1 was done using clone BE29G1 at 10 
ug/mL, 166623 at 1 ug/mL or R6.5 at 10 ug/mL or through CD28 clone 37.51 at 2.5 
ug/mL.  6.7) Representative dot plots of memory phenotypes generated after CD4+ T 
splenocytes were stimulated for 7 days through CD3, CD3+ICAM-1 (166623) or CD3+ 
CD28.  6.8-6.9) Percent of memory cells generated after CD4+ T splenocytes (6.8) or 
CD4+CD62L+ naïve T splenocytes (6.9) were stimulated for 7 days through antibody 
combinations indicated.  
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blocking antibody in solution and is known to bind to a different ICAM-1 epitope than 
the previously tested YN1 clone (16).  For this experiment we examined combinations of 
three different concentrations of anti-CD3 clone 500A2 (0.05 ug/mL, 0.1 ug/mL, 0.25 
ug/mL) and three concentrations of anti-ICAM-1 (5 ug/mL, 10 ug/mL, 20 ug/mL) with 
and without the presence of recombinant mouse IL-2.  We also wanted to determine if 
there is a difference between costimulation with purified or functional grade KAT-1 
clone.  Functional grade KAT-1 antibody contains no sodium azide or carrier 
proteins/stabilizers and has an extremely low endotoxin level less than 0.001 ng/ug of 
antibody.   
 In general, we found that stimulating CD5+ T cells through CD3+ICAM-1, 
purified KAT-1 clone,  yielded a greater percentage memory phenotype than CD3 alone 
or CD3+CD28.  Lower concentrations of stimulating CD3 in conjunction with ICAM-1 
produced the most memory cells which then dropped as anti-CD3 increased and the 
inverse was seen with a step-wise increase with increasing anti-ICAM-1 concentrations, 
therefore, the best memory T cell generating combination was 0.05 ug/mL of anti-CD3 
and 10-20 ug/mL of anti-ICAM-1 (Fig. 6.10).  The addition of recombinant mouse IL-2 
actually reduced the memory cell production with each stimulation combination 
(Fig.6.10).  Also, increasing the concentration of stimulating anti-CD3 alone, with or 
without exogenous IL-2, did not seem to modulate the memory cell percent (Fig. 6.10).  
The trend seen with stimulating through purified KAT-1 ICAM-1 was largely repeated 
with functional grade KAT-1 and the percent of memory cells generated with each 
concentration was similar to purified KAT-1, indicating little difference in the stimulation 
between the two forms of the antibody (Fig. 6.11).  With most KAT-1 clone 
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concentrations, the 10 ug/mL concentration either yielded a very similar or better 
memory production to 20 ug/mL.  Given the lower amount of stimulating antibody 
needed, 10 ug/mL would be the more economical choice for the optimal anti-ICAM-1 
concentration.  As expected, the addition of recombinant human IL-2 instead of mouse 
IL-2 decreased the percent of memory cells that were produced (data not shown).   
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Figure 6.10 
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Figure 6.11 
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Figure 6.10-6.11. Titration of CD3 (500A2) and ICAM-1 (purified and functional grade, 
KAT) stimulating antibodies and mouse IL-2 on CD5+ Balb/c splenocytes.  Stimulation 
of CD5+ T cells through CD3 was performed using clone 500A2 and through ICAM-1 
using clone KAT-1 at concentrations indicated. Figure 6.10 uses purified KAT-1 
antibody and 6.11 uses functional grade KAT-1 antibody.  Mouse recombinant IL-2 was 
used at a concentration of 20 ng/mL.  Percent of memory cells generated after CD5+ T 
splenocytes were stimulated for 7 days through antibody combinations indicated.  
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Discussion 
 The goal of this chapter was to determine the optimal protocol for stimulating 
mouse T cells through ICAM-1 to induce them to differentiate to a memory phenotype.  
We observed that various concentrations and stimulating antibody clones were able to 
induce T cell activation.  Based on CD69 expression, proliferation experiments 
performed by Kelli Williams and cell differentiation presented here we conclude that 
0.05 ug/mL of 500A2 is the best stimulating CD3 antibody.  ICAM-1 clones and 
concentrations that worked the best based on the same parameters were 10 ug/mL of 
BE29G1, 1 ug/mL of 166623, 10 ug/mL of R6.5 or 10 ug/mL KAT-1.   
 It is noteworthy that a part of this study was to look for the ability of either mouse 
CD4+ T cells or CD4+CD62L+ T cells to differentiate to a regulatory phenotype using 
the same parameters.  This was another portion of the work that was performed by Kelli 
Williams.  Kelli found that, unlike with human T cells (19), costimulation through 
ICAM-1 of mouse T cells did not induce a regulatory phenotype.  This discrepancy 
illustrates how ICAM-1 signals differently between species and the importance of 
seeking out various anti-ICAM-1 clones for the most efficient stimulation since different 
antibody clones may bind to different epitopes on the costimulatory molecule, thus 
altering signal sent into the cell. 
 The ability to stimulate murine T cells in vitro through ICAM-1 to induce 
differentiation to a memory phenotype has many possibilities in helping to understand the 
immune response better or for the development of therapies that can be used in mouse 
disease models.  Adoptive transfer of memory T cells generated with ICAM-1 
costimulation in vitro could be utilized to determine homing patterns of memory cells in 
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vivo and possibly support our chemokine receptor observations in humans.  Along the 
same lines, we could track T cells activated through ICAM-1 as they fight infection much 
like Ciabattini, et al. who tracked T cells primed in vitro following immunization in vivo 
(20).   Memory T cells generated through ICAM-1 could also be used in studies for 
development of immunotherapy for cancers.  For example, tumor specific T cells could 
be selected  in vitro using ICAM-1 costimulation and activation in the presence of tumor 
antigen and then applied in vivo as a T cell therapy to a mouse model such as the 4T1 
breast cancer model in Balb/c mice (21).  In summary, defining the parameters for 
ICAM-1 costimulation and differentiation to a memory cell phenotype is an important 
first step in our ability to understand the adaptive immune response, how it is affected by 
costimulation and study disease with the use of mouse models. 
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Summary 
 The work in this dissertation illustrates an important role for ICAM-1 as a 
costimulatory molecule in T cell activation.  We demonstrated that blocking the ICAM-
1:LFA-1 interaction rendered T cells unresponsive in a NOD mouse model in vivo and in 
vitro and with human cells stimulated in vitro.  The blocking peptides also inhibited or 
stopped T cell infiltration into the islets of the treated mice.  Also, T splenocytes from 
peptide treated NOD mice did not initiate T1D when adoptively transferred into T cell 
deficient NOD-SCID mice compared to T splenocytes from saline control mice. 
 Costimulation through ICAM-1 of human CD4+ naïve T cells initiated 
differentiation to a memory phenotype days after stimulation but required constant, long-
term stimulation to generate larger numbers of memory cells.  This suggests different 
pathways for differerntiation to a memory phenotype.  Even though costimulation 
through CD28 generated memory cell numbers statistically similar to long-term 
stimulation a few days before ICAM-1, the total number of memory cells with CD28 was 
lower than that from ICAM-1 after 14 days of continual stimulaton.  Costimulation 
through ICAM-1 gave rise to a memory population that exhibited lymph node homing 
potential indicating that ICAM-1 differentiates naive T cells to a central memory 
phenotype. 
 ICAM-1 costimulation induces differentiation of naïve T cells from older 
individuals to a memory phenotype better than CD28.  According to preliminary data, 
these cells are protected from apoptosis and proliferate better than differentiating cells 
costimulated through LFA-1 or CD28 therefore leading to a larger population of viable 
cells.  These data have promising implications in understanding how the immune system 
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ages and how to develop new stratagies to fight infection, cancer and boost vaccine 
response as we age.   
